US5874290A - Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon - Google Patents
Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon Download PDFInfo
- Publication number
- US5874290A US5874290A US08/747,121 US74712196A US5874290A US 5874290 A US5874290 A US 5874290A US 74712196 A US74712196 A US 74712196A US 5874290 A US5874290 A US 5874290A
- Authority
- US
- United States
- Prior art keywords
- protein
- nucleic acid
- gene
- expression
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101001099888 Homo sapiens Ras-related protein Rab-3D Proteins 0.000 title claims abstract description 578
- 125000003275 alpha amino acid group Chemical group 0.000 title claims abstract 3
- 239000002773 nucleotide Substances 0.000 title claims description 47
- 125000003729 nucleotide group Chemical group 0.000 title claims description 47
- 238000000034 method Methods 0.000 title description 128
- 208000003174 Brain Neoplasms Diseases 0.000 title description 38
- 102100038474 Ras-related protein Rab-3D Human genes 0.000 claims abstract description 520
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 178
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 174
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 165
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 165
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 91
- 239000012634 fragment Substances 0.000 claims abstract description 86
- 230000000295 complement effect Effects 0.000 claims abstract description 18
- 108020004414 DNA Proteins 0.000 claims description 64
- 108091026890 Coding region Proteins 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 78
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 77
- 230000001225 therapeutic effect Effects 0.000 abstract description 72
- 241000282414 Homo sapiens Species 0.000 abstract description 65
- 208000035475 disorder Diseases 0.000 abstract description 63
- 201000011510 cancer Diseases 0.000 abstract description 34
- 239000000203 mixture Substances 0.000 abstract description 33
- 238000011282 treatment Methods 0.000 abstract description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 26
- 208000005017 glioblastoma Diseases 0.000 abstract description 23
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract description 14
- 241000894007 species Species 0.000 abstract description 13
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 238000002405 diagnostic procedure Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 126
- 230000014509 gene expression Effects 0.000 description 126
- 235000018102 proteins Nutrition 0.000 description 87
- 210000001519 tissue Anatomy 0.000 description 71
- 150000001413 amino acids Chemical group 0.000 description 67
- 229940024606 amino acid Drugs 0.000 description 47
- 235000001014 amino acid Nutrition 0.000 description 46
- 230000000692 anti-sense effect Effects 0.000 description 42
- 238000003556 assay Methods 0.000 description 41
- 230000006870 function Effects 0.000 description 40
- 239000013598 vector Substances 0.000 description 40
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 36
- 238000003752 polymerase chain reaction Methods 0.000 description 34
- 239000000523 sample Substances 0.000 description 34
- 230000027455 binding Effects 0.000 description 33
- 238000009396 hybridization Methods 0.000 description 33
- 238000000338 in vitro Methods 0.000 description 32
- 210000004556 brain Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 108091034117 Oligonucleotide Proteins 0.000 description 24
- 239000002299 complementary DNA Substances 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 24
- 239000013615 primer Substances 0.000 description 24
- 230000004663 cell proliferation Effects 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 238000001415 gene therapy Methods 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 19
- 230000001605 fetal effect Effects 0.000 description 18
- 230000003902 lesion Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 210000000130 stem cell Anatomy 0.000 description 17
- 230000036210 malignancy Effects 0.000 description 16
- 238000003018 immunoassay Methods 0.000 description 15
- 238000010171 animal model Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 14
- 238000003757 reverse transcription PCR Methods 0.000 description 14
- 208000037765 diseases and disorders Diseases 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 238000000636 Northern blotting Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 206010003571 Astrocytoma Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000000069 prophylactic effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000002105 Southern blotting Methods 0.000 description 10
- 210000005013 brain tissue Anatomy 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000003211 malignant effect Effects 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- 241000701161 unidentified adenovirus Species 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000005714 functional activity Effects 0.000 description 9
- 238000002744 homologous recombination Methods 0.000 description 9
- 230000006801 homologous recombination Effects 0.000 description 9
- 238000000099 in vitro assay Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 230000001177 retroviral effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000007469 Actins Human genes 0.000 description 8
- 108010085238 Actins Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 208000032612 Glial tumor Diseases 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 7
- 206010054949 Metaplasia Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 230000015689 metaplastic ossification Effects 0.000 description 7
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 7
- 238000010369 molecular cloning Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 206010058314 Dysplasia Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 208000000172 Medulloblastoma Diseases 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 210000001130 astrocyte Anatomy 0.000 description 6
- 238000000211 autoradiogram Methods 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 230000003412 degenerative effect Effects 0.000 description 6
- -1 lambda) Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 206010027191 meningioma Diseases 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 230000001855 preneoplastic effect Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000972773 Aulopiformes Species 0.000 description 5
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 5
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 238000007899 nucleic acid hybridization Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 102000043276 Oncogene Human genes 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000329 molecular dynamics simulation Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108091023045 Untranslated Region Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000007818 agglutination assay Methods 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical class NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 2
- 208000000321 Gardner Syndrome Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000013602 bacteriophage vector Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 description 2
- 201000010983 breast ductal carcinoma Diseases 0.000 description 2
- 208000011803 breast fibrocystic disease Diseases 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical class OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 208000030212 nutrition disease Diseases 0.000 description 2
- 208000019180 nutritional disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000002729 polyribosome Anatomy 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 230000003161 proteinsynthetic effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical class C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical class OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical class OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical class CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001907 Amblyopia alcohol Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000005692 Bloom Syndrome Diseases 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000001843 Carotid Body Tumor Diseases 0.000 description 1
- 208000037211 Carotid body tumour Diseases 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000037564 High-grade astrocytoma Diseases 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical class O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical class CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical class OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical class NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Chemical class CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical class CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Chemical class OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Chemical class NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Chemical class OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010077895 Sarcosine Chemical class 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010058571 Spinal cord infarction Diseases 0.000 description 1
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000010045 Wernicke encephalopathy Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000026555 breast adenosis Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 208000009885 central pontine myelinolysis Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Chemical class OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Chemical class ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates t o a novel D2-2 gene and its encoded protein product(s), as well as derivatives and analogs thereof. Production of D2-2 proteins, derivatives, and antibodies is also provided.
- the invention further relates to therapeutic compositions and methods of diagnosis and therapy.
- Brain tumors are among the leading cause of death among young children and adults.
- a survey by the American Cancer Society has documented that 13,300 people died of brain tumors in 1995 and over 17,900 will die in 1996 (Parker et al., 1996, CA Cancer J. Clin., 46:5-28).
- the number of deaths due to brain tumors has been increasing at a significant rate each year. On average, 25,000 Americans are diagnosed with brain cancer yearly. Brain tumors claim the lives of more children than any other form of cancer except leukemia.
- Glioblastoma multiforme are high grade astrocytomas that grow very rapidly and contain cells that are very malignant (Thapar and Laws, 1993, CA Cancer J. Clin., 43:263-271).
- the molecular basis of glioblastoma multiforme occurrence may involve systematic events at the chromosomal level or at a gene expression level. These may include inactivation of tumor suppressor genes, activation of oncogenes or specific translocations at the chromosomal level.
- Some genetic changes at the chromosomal level and gene expression level have been well documented for other brain tumors (Furnari et al., 1995, Cancer Surv., 25:233-275).
- glioblastoma multiforme A number of other genes such as EGFR, CD44, ⁇ 4 integrins, membrane-type metalloproteinase (MT-MMP), p21, p16, p15, myc, and VEGF have been shown to be overexpressed in different types of brain tumors (Faillot et al., 1996 Neurosurgery, 39:478-483; Eibl et al., 1995, J.
- genes such as p53 show mutations in the majority of brain tumors (Bogler et al., supra). How the interplay of one or more of these genes leads to tumorigenesis is not known but most likely multiple steps are required for neoplastic transformation. The exact series of events that lead to initiation or progression of glioblastoma are not known at present and useful markers for early detection of brain tumors are lacking.
- the present invention relates to nucleotide sequences of D2-2 genes (human D2-2 and D2-2 homologs of other species), and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. Nucleic acids hybridizable to or complementary to the foregoing nucleotide sequences are also provided.
- the D2-2 gene is a human gene and the D2-2 protein is a human protein.
- D2-2 is a gene provided by the present invention, that is expressed at high levels in glioblastoma multiforme tissue as well as certain others forms of tumors and cancers.
- the invention also relates to D2-2 derivatives and analogs that are functionally active, i.e., they are capable of displaying one or more known functional activities associated with a full-length (wild-type) D2-2 protein.
- Such functional activities include but are not limited to antigenicity ability to bind (or compete with D2-2 for binding) to an anti-D2-2 antibody!, immunogenicity (ability to generate antibody which binds to D2-2), and ability to bind (or compete with D2-2 for binding) to a receptor/ligand for D2-2.
- the invention further relates to fragments (and derivatives and analogs thereof) of D2-2 which comprise one or more domains of a D2-2 protein.
- Antibodies to D2-2, and to D2-2 derivatives and analogs, are additionally provided.
- the present invention also relates to therapeutic and diagnostic methods and compositions based on D2-2 proteins and nucleic acids.
- Therapeutic compounds of the invention include but are not limited to D2-2 proteins and analogs and derivatives (including fragments) thereof; antibodies thereto; nucleic acids encoding the D2-2 proteins, analogs, or derivatives; and D2-2 antisense nucleic acids.
- the invention provides for treatment of disorders of overproliferation (e.g., tumors, cancer and hyperproliferative disorders) by administering compounds that decrease or antagonize (inhibit) D2-2 function (e.g., antibodies, antisense nucleic acids, ribozymes).
- disorders of overproliferation e.g., tumors, cancer and hyperproliferative disorders
- compounds that decrease or antagonize (inhibit) D2-2 function e.g., antibodies, antisense nucleic acids, ribozymes.
- the invention also provides methods of treatment of disorders involving deficient cell proliferation (growth) or in which cell proliferation is otherwise desired (e.g., degenerative disorders, growth deficiencies, lesions, physical trauma) by administering compounds that promote D2-2 activity (e.g., an agonist of D2-2; nucleic acids that encode D2-2).
- diseases involving deficient cell proliferation (growth) or in which cell proliferation is otherwise desired e.g., degenerative disorders, growth deficiencies, lesions, physical trauma
- compounds that promote D2-2 activity e.g., an agonist of D2-2; nucleic acids that encode D2-2.
- Promoting D2-2 function can also be done to grow larger animals and plants, e.g., those used as food or material sources.
- Animal models, diagnostic methods and screening methods for predisposition to disorders, and methods for identification of D2-2 agonists and antagonists, are also provided by the invention.
- underscoring or italicizing the name of a gene shall indicate the gene, in contrast to its encoded protein product, which is indicated by the name of the gene in the absence of any underscoring or italicizing.
- D2-2 nucleotides or coding sequences DNA sequences encoding D2-2 mRNA transcripts, protein, polypeptide or peptide fragments of D2-2 protein, and D2-2 fusion proteins.
- D2-2 nucleotide sequences encompass DNA, including genomic DNA (e.g. the D2-2 gene) and cDNA.
- D2-2 gene products, e.g., transcripts and the D2-2 protein.
- Polypeptides or peptide fragments of the protein are referred to as D2-2 polypeptides or D2-2 peptides.
- Fusions of D2-2 protein, polypeptides, or peptide fragments to an unrelated protein are referred to herein as D2-2 fusion proteins.
- CD cytoplasmic domain
- MTB multiple tissue blot
- MTT meningioma tumor tissue
- NBT normal brain tissue
- DBTRG-05MG glioblastoma multiforme
- Hs 683 glioma
- IMR-32 neuroblastoma
- PFSK-1 primitive neuroectodermal tumor
- SW 1783 astrocytoma grade III
- FIGS. 1A-B illustrates identification of differentially expressed genes from glioblastoma multiforme tumor tissue and normal brain tissue using differential display-PCR (DD-PCR).
- Total RNA from tissue samples (PNCF 014) was isolated using the GITC/CsCl 2 method (as described in text Section 6.1.2).
- DD-PCR was performed with one 3' primer BT-3(2), (5'T(T)18NG3') and three 5' primers (BT-8, 5'NTACTGATCCATGACA3' (SEQ ID NO: 3); BT-10, 5'NGCTGCTCTCATACT3' (SEQ ID NO: 4); and BT-12, 5'NTGATCTAAGGCACATA3' (SEQ ID NO: 5). Shown in FIG.
- FIG. 1A is an autoradiogram of DD-PCR using the specific 5' primers as indicated at the bottom of the figure. Note overexpression of the D2-2 gene in tumor (T) compared to normal (N) brain tissue.
- FIGS. 2A-C demonstrates that Clone D2-2 is overexpressed in glioblastoma tumor tissue compared to normal brain, meningioma and B cell lymphoma.
- FIGS. 2A and 2B are autoradiograms of a RT-PCR for D2-2 (FIG. 2A) and D1-2 (FIG. 2B).
- FIG. 2C represents the relative expression of D2-2. See text Section 6.1.3. for experimental details.
- FIG. 3 shows the partial nucleotide sequence and deduced amino acid sequence of clone D2-2.
- An EcoRI and XbaI fragment (750 bp) of clone D2-2 was used for screening a human fetal brain library.
- a 2.0 kb EcoRI-XhoI fragment (SEQ ID NO: 1) was isolated and sequenced to completion by Sequetech (Mountain View, Calif.). The open reading frame is indicated by the deduced amino acid sequence below the nucleotide sequence.
- a portion (144 bp) (SEQ ID NO: 2) of the original D2-2 fragment sequence (250 bp) isolated by DD-PCR is underlined.
- Clone D2-2 contains three nucleotide sequences encoding HLA-A2 + motifs (SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18). These sequences are bracketed and overlined. The deduced amino acid sequence for each is indicated below it. Amino acids 8-16 are represented by SEQ ID NO: 15, amino acids 27-35 are represented by SEQ ID NO: 17, and amino acids 56-63 are represented by SEQ ID NO: 19.
- FIGS. 4A-C shows expression of D2-2 in tumor tissues. Total RNA was isolated from several normal and tumor tissues. RT-PCR for D2-2 and D1-2 was performed as described in text Section 6.1.3.
- FIG. 4A shows D2-2 expression;
- FIG. 4B shows D1-2 expression.
- FIG. 4C is a bar graph showing relative expression of D2-2 after correction for gel loading based on D1-2 expression.
- FIGS. 5A-C illustrates expression of D2-2 in brain tumor cell lines and normal fetal human astrocytes.
- FIGS. 5A-B is an autoradiogram of a Southern blot of D2-2 expression (FIG. 5A) and of D1-2 expression (FIG. 5B) in various brain tumor cell lines and normal fetal human astrocytes.
- FIG. 5C represents the relative expression of D2-2 in respective cell lines after correction for gel loading based on D1-2 expression.
- FIGS. 6A-C shows expression of D2-2 in human cancer cell lines.
- FIGS. 6A-B is an autoradiogram of a Northern blot of D2-2 expression (FIG. 6A) and of ⁇ actin expression (FIG. 6B), which serves as an internal control for gel loading in various human cancer cell lines.
- FIG. 6C is a bar graph of relative expression of D2-2 after correction for gel loading based on ⁇ actin expression. See text Section 6.1.5 for experimental details.
- FIGS. 7A-C shows expression of D2-2 in different regions of the brain.
- FIGS. 7A-B is an autoradiogram of a Northern blot of D2-2 expression (FIG. 7A) and of ⁇ actin expression (FIG. 7B), which serves as an internal control for gel loading.
- FIG. 7C is a bar graph of relative expression of D2-2 after correction for gel loading based on ⁇ actin expression. See text Section 6.1.5 for experimental details.
- FIGS. 8A-C shows expression of D2-2 in normal human tissues.
- FIG. 8A-B is an autoradiogram of a Northern blot of D2-2 expression (FIG. 8A) and of ⁇ actin expression (FIG. 8B), which serves as an internal control for gel loading.
- FIG. 8C is a bar graph of the relative expression of D2-2 after correction for gel loading based on ⁇ actin expression. See Section 6.1.5 for experimental details.
- FIG. 9 illustrates expression of clone D2-2 in fetal compared to adult tissue. See text Section 6.1.6 for experimental details.
- the present invention relates to nucleotide sequences of D2-2 genes, and amino acid sequences of their encoded proteins.
- the invention further relates to fragments and other derivatives, and analogs, of D2-2 proteins.
- Nucleic acids encoding such fragments or derivatives are also within the scope of the invention.
- the invention provides D2-2 genes and their encoded proteins of humans and related genes (homologs) in other species.
- the D2-2 genes and proteins are from vertebrates, or more particularly, mammals.
- the D2-2 genes and proteins are of human origin. Production of the foregoing nucleic acids, proteins and derivatives, e.g., by recombinant methods, is provided.
- D2-2 is a gene provided by the present invention, identified by the method of the invention, and that is expressed at high levels in glioblastoma multiforme tissue as well as certain others forms of tumors and cancers.
- the invention also relates to D2-2 derivatives and analogs of the invention which are functionally active, i.e., they are capable of displaying one or more functional activities described herein associated with a full-length (wild-type) D2-2 protein.
- Such functional activities include but are not limited to antigenicity, i.e., ability to bind (or compete with D2-2 for binding) to an anti-D2-2 antibody, immunogenicity, i.e., ability to generate antibody which binds to D2-2, and ability to bind (or compete with D2-2 for binding) to a receptor/ligand for D2-2.
- the invention further relates to fragments (and derivatives and analogs thereof) of D2-2 which comprise one or more domains of the D2-2 protein.
- Antibodies to D2-2, its derivatives and analogs, are additionally provided.
- the present invention also relates to therapeutic and diagnostic methods and compositions based on D2-2 proteins and nucleic acids and anti-D2-2 antibodies.
- the invention provides for treatment of disorders of overproliferation (e.g., cancer and hyperproliferative disorders) by administering compounds that decrease D2-2 activity (e.g., antibodies, D2-2 antisense nucleic acids).
- the invention also provides methods of treatment of disorders involving deficient cell proliferation or in which cell proliferation (growth) is otherwise desirable (e.g., growth deficiencies, degenerative disorders, lesions, physical trauma) by administering compounds that promote D2-2 function.
- growth e.g., growth deficiencies, degenerative disorders, lesions, physical trauma
- Promotion of D2-2 function can also be done to grow larger farm animals and plants.
- Animal models, diagnostic methods and screening methods for predisposition to disorders are also provided by the invention.
- the invention is illustrated by way of examples infra which disclose, inter alia, the isolation and characterization of D2-2, and patterns of expression of D2-2 in certain tumors and during development (see Section 6).
- D2-2 nucleic acids comprise the cDNA sequences of SEQ ID NO: 1, or the coding regions thereof, or nucleotide sequences acids encoding a D2-2 protein (e.g., a protein having the sequence of SEQ ID NO: 7).
- the invention provides purified nucleic acids consisting of at least 6 contiguous nucleotides (i.e., a hybridizable portion) of a D2-2 sequence; in other embodiments, the nucleic acids consist of contiguous nucleotides of at least 8 nucleotides, 25 nucleotides, 50 nucleotides, 100 nucleotides, 150 nucleotides, 200 nucleotides, or 250 nucleotides of a D2-2 sequence. In another embodiment, the nucleic acids are smaller than 35, 200 or 250 nucleotides in length. Nucleic acids can be single or double stranded. The invention also relates to nucleic acids hybridizable to or complementary to the foregoing sequences.
- nucleic acids are provided which comprise a sequence complementary to at least 10, 25, 50, 100, 200, or 250 nucleotides of a D2-2 gene.
- a nucleic acid which is hybridizable to a D2-2 nucleic acid e.g., having sequence SEQ ID NO: 2
- a nucleic acid encoding a D2-2 derivative under conditions of low stringency is provided.
- Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 ⁇ 10 6 cpm 32 P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40° C., and then washed for 1.5 h at 55° C. in a solution containing 2 ⁇ SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60° C.
- Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65°-68° C. and reexposed to film.
- Other conditions of low stringency which may be used are well known in the art (e.g., as employed for cross-species hybridizations).
- a nucleic acid which is hybridizable to a D2-2 nucleic acid under conditions of high stringency is provided.
- procedures using such conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65° C. in buffer composed of 6 ⁇ SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65° C.
- nucleic acid which is hybridizable to a D2-2 nucleic acid under conditions of moderate stringency is provided.
- Various other stringency conditions which promote nucleic acid hybridization can be used. For example, hybridization in 6 ⁇ SSC at about 45° C., followed by washing in 2 ⁇ SSC at 50° C. may be used.
- the salt concentration in the wash step can range from low stringency of about 5 ⁇ SSC at 50° C., to moderate stringency of about 2 ⁇ SSC at 50° C., to high stringency of about 0.2 ⁇ SSC at 50° C.
- the temperature of the wash step can be increased from low stringency conditions at room temperature, to moderately stringent conditions at about 42° C., to high stringency conditions at about 65° C.
- Other conditions include, but are not limited to, hybridizing at 68° C.
- Nucleic acids encoding derivatives and analogs of D2-2 proteins are additionally provided.
- a "nucleic acid encoding a fragment or portion of a D2-2 protein” shall be construed as referring to a nucleic acid encoding only the recited fragment or portion of the D2-2 protein and not the other contiguous portions of the D2-2 protein as a continuous sequence.
- D2-2 nucleic acids comprising regions conserved between other D2-2 nucleic acids, of the same or different species, are also provided.
- Nucleic acids encoding one or more D2-2 domains are provided.
- an expression library is constructed by methods known in the art. For example, mRNA (e.g., human) is isolated, cDNA is made and ligated into an expression vector (e.g., a bacteriophage derivative) such that it is capable of being expressed by the host cell into which it is then introduced. Various screening assays can then be used to select for the expressed D2-2 product. In one embodiment, anti-D2-2 antibodies can be used for selection.
- PCR polymerase chain reaction
- Oligonucleotide primers representing known D2-2 sequences can be used as primers in PCR.
- the oligonucleotide primers represent at least part of the D2-2 sequence presented in FIG. 3 (SEQ ID NO: 1).
- the synthetic oligonucleotides may be utilized as primers to amplify by PCR sequences from a source (RNA or DNA), preferably a cDNA library, of potential interest.
- PCR can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp).
- the DNA being amplified can include mRNA, cDNA, or genomic DNA from any eukaryotic species.
- That segment may be molecularly cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described infra. In this fashion, additional genes encoding D2-2 proteins and D2-2 analogs may be identified.
- Any eukaryotic cell potentially can serve as the nucleic acid source for the molecular cloning of the D2-2 gene.
- the nucleic acid sequences encoding D2-2 can be isolated from vertebrate sources, including mammalian sources, such as porcine, bovine, feline, and equine, canine, human, as well as additional primate sources, avian, reptilian, amphibian, piscine, etc. sources, non-vertebrate sources such as insects, from plants, etc.
- the DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA "library”), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell.
- cloned DNA e.g., a DNA "library”
- chemical synthesis e.g., chemical synthesis
- cDNA cloning e.g., a DNA "library”
- Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.
- DNA fragments are generated, some of which will encode the desired gene.
- the DNA may be cleaved at specific sites using various restriction enzymes.
- DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication.
- the linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.
- identification of the specific DNA fragment containing the desired gene may be accomplished in a number of ways. For example, if an amount of a portion of a D2-2 (of any species) gene or its specific RNA, or a fragment thereof (see Section 5.6), is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). Those DNA fragments with substantial homology to the probe will hybridize.
- cDNA clones, or DNA clones which hybrid-select the proper mRNAs can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, promotion of cell proliferation activity, substrate binding activity, or antigenic properties of D2-2. If an antibody to D2-2 is available, the D2-2 protein may be identified by binding of labeled antibody to the putatively D2-2 synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.
- ELISA enzyme-linked immunosorbent assay
- the D2-2 gene can also be identified by mRNA selection by nucleic acid hybridization followed by in vitro translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified D2-2 DNA of another species (e.g., human, mouse, etc.). Immunoprecipitation analysis or functional assays (e.g., aggregation ability in vitro; binding to receptor; see infra) of the in vitro translation products of the isolated products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against D2-2 protein.
- a radiolabelled D2-2 cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabelled mRNA or cDNA may then be used as a probe to identify the D2-2 DNA fragments from among other genomic DNA fragments.
- RNA for cDNA cloning of the D2-2 gene can be isolated from cells which express D2-2. Other methods are possible and within the scope of the invention.
- the identified and isolated gene can then be inserted into an appropriate cloning vector.
- vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene).
- the insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini.
- the ends of the DNA molecules may be enzymatically modified.
- any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.
- the cleaved vector and D2-2 gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.
- the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionization, can be done before insertion into the cloning vector.
- transformation of host cells with recombinant DNA molecules that incorporate the isolated D2-2 gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene.
- the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.
- the D2-2 sequences provided by the present invention include those nucleotide sequences encoding substantially the same amino acid sequences as found in native D2-2 proteins, and those encoded amino acid sequences with functionally equivalent amino acids, as well as those encoding other D2-2 derivatives or analogs, as described in Sections 5.6 and 5.6.1 infra for D2-2 derivatives and analogs.
- the nucleotide sequence coding for a D2-2 protein or a functionally active analog or fragment or other derivative thereof can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence.
- the necessary transcriptional and translational signals can also be supplied by the native D2-2 gene and/or its flanking regions.
- a variety of host-vector systems may be utilized to express the protein-coding sequence.
- mammalian cell systems infected with virus e.g., vaccinia virus, adenovirus, etc.
- insect cell systems infected with virus e.g., baculovirus
- microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA.
- the expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.
- the human D2-2 gene is expressed, or a sequence encoding a functionally active portion of human D2-2.
- a fragment of D2-2 comprising a domain of the D2-2 protein is expressed.
- any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination). Expression of nucleic acid sequence encoding a D2-2 protein or peptide fragment may be regulated by a second nucleic acid sequence so that the D2-2 protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a D2-2 protein may be controlled by any promoter/enhancer element known in the art.
- Promoters which may be used to control D2-2 expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A.
- prokaryotic expression vectors such as the ⁇ -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A.
- promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp.
- mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel.
- beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).
- a vector in a specific embodiment, comprises a promoter operably linked to a D2-2-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).
- an expression construct is made by subcloning a D2-2 coding sequence into the EcoRI restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the D2-2 protein product from the subclone in the correct reading frame.
- Expression vectors containing D2-2 gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences.
- the presence of a D2-2 gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted D2-2 gene.
- the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a D2-2 gene in the vector.
- certain "marker" gene functions e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
- recombinant expression vectors can be identified by assaying the D2-2 product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the D2-2 protein in in vitro assay systems, e.g., binding with anti-D2-2 antibody, promotion of cell proliferation.
- the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
- a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered D2-2 protein may be controlled.
- different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.
- the D2-2 protein, fragment, analog, or derivative may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)).
- a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.
- a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer.
- cDNA and genomic sequences can be cloned and expressed.
- the invention provides amino acid sequences of D2-2, preferably human D2-2, and fragments and derivatives thereof which comprise an antigenic determinant (i.e., can be recognized by an antibody) or which are otherwise functionally active, as well as nucleic acid sequences encoding the foregoing.
- "Functionally active" D2-2 material as used herein refers to that material displaying one or more functional activities associated with a full-length (wild-type) D2-2 protein, e.g., promotion of cell proliferation, binding to a D2-2 substrate or D2-2 binding partner, antigenicity (binding to an anti-D2-2 antibody), immunogenicity, etc.
- the invention provides proteins comprising, having, or consisting essentially of a sequence of amino acids having a sequence at least 70%, preferably 80% identical with SEQ ID NO: 7.
- the invention provides fragments of a D2-2 protein consisting of at least 6 amino acids, 10 amino acids, 50 amino acids, or of at least 75 amino acids.
- the invention provides proteins comprising, having, or consisting essentially of a sequence of amino acids 100% identical with SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 19, or any combination of the foregoing, of a D2-2 protein. Fragments or proteins comprising such sequences are particularly advantageously used for immunotherapy as described below e.g., in Section 5.11. Fragments, or proteins comprising fragments, lacking some or all of the foregoing regions of a D2-2 protein are also provided. Nucleic acids encoding the foregoing are provided.
- the gene product can be analyzed. This is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay, etc.
- the D2-2 protein may be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
- chromatography e.g., ion exchange, affinity, and sizing column chromatography
- centrifugation e.g., centrifugation
- differential solubility e.g., differential solubility
- the functional properties may be evaluated using any suitable assay (see Section 5.7).
- the amino acid sequence of the protein can be deduced from the nucleotide sequence of the chimeric gene contained in the recombinant.
- the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, Nature 310:105-111).
- native D2-2 proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).
- such D2-2 proteins whether produced by recombinant DNA techniques or by chemical synthetic methods or by purification of native proteins, include but are not limited to those containing, as a primary amino acid sequence, all or part of the amino acid sequence substantially as depicted in FIG. 3 (SEQ ID NO: 7), as well as fragments and other derivatives, and analogs thereof, including proteins homologous thereto.
- the structure of the D2-2 gene and protein can be analyzed by various methods known in the art.
- the cloned DNA or cDNA corresponding to the D2-2 gene can be analyzed by methods including but not limited to Southern hybridization (Southern, E. M., 1975, J. Mol. Biol. 98:503-517), Northern hybridization (see e.g., Freeman et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:4094-4098), restriction endonuclease mapping (Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), and DNA sequence analysis. Polymerase chain reaction (PCR; U.S. Pat. Nos.
- Southern hybridization can be used to determine the genetic linkage of D2-2.
- Northern hybridization analysis can be used to determine the expression of the D2-2 gene.
- Various cell types, at various states of development or activity can be tested for D2-2 expression.
- the stringency of the hybridization conditions for both Southern and Northern hybridization can be manipulated to ensure detection of nucleic acids with the desired degree of relatedness to the specific D2-2 probe used. Modifications of these methods and other methods commonly known in the art can be used.
- Restriction endonuclease mapping can be used to roughly determine the genetic structure of the D2-2 gene. Restriction maps derived by restriction endonuclease cleavage can be confirmed by DNA sequence analysis.
- DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Pat. No. 4,795,699), or use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, Calif.).
- the amino acid sequence of the D2-2 protein can be derived by deduction from the DNA sequence, or alternatively, by direct sequencing of the protein, e.g., with an automated amino acid sequencer.
- the D2-2 protein sequence can be further characterized by a hydrophilicity analysis (Hopp, T. and Woods, K., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824).
- a hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the D2-2 protein and the corresponding regions of the gene sequence which encode such regions.
- Manipulation, translation, and secondary structure prediction, open reading frame prediction and plotting, as well as determination of sequence homologies can also be accomplished using computer software programs available in the art.
- D2-2 protein may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen.
- Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
- antibodies to a human D2-2 protein are produced.
- antibodies to a domain of a D2-2 protein are produced.
- fragments of a D2-2 protein identified as hydrophilic are used as immunogens for antibody production.
- the antibody to a human D2-2 protein is a bispecific antibody (see generally, e.g. Fanger and Drakeman, 1995, Drug News and Perspectives 8: 133-137).
- a bispecific antibody is genetically engineered to recognize both (1) a human D2-2 epitope and (2) one of a variety of "trigger" molecules, e.g. Fc receptors on myeloid cells, and CD3 and CD2 on T cells, that have been identified as being able to cause a cytotoxic T-cell to destroy a particular target.
- Such bispecific antibodies can be prepared either by chemical conjugation, hybridoma, or recombinant molecular biology techniques known to the skilled artisan.
- polyclonal antibodies to a D2-2 protein or derivative or analog may be obtained.
- various host animals can be immunized by injection with the native D2-2 protein, or a synthetic version, or derivative (e.g., fragment) thereof, including but not limited to rabbits, mice, rats, etc.
- adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.
- BCG Bacille Calmette-Guerin
- any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used.
- the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies Colde et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
- monoclonal antibodies can be produced in germ-free animals utilizing technology described in PCT/US90/02545.
- human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96).
- human hybridomas Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030
- transforming human B cells with EBV virus in vitro Cold-et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96.
- techniques developed for the production of "chimeric antibodies” (Morrison et al., 1984, PROC.
- techniques described for the production of single chain antibodies can be adapted to produce D2-2-specific single chain antibodies.
- An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for D2-2 proteins, derivatives, or analogs.
- Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
- such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.
- screening for the desired antibody can be accomplished by techniques known in the art, e.g. ELISA (enzyme-linked immunosorbent assay).
- ELISA enzyme-linked immunosorbent assay
- an antibody that specifically binds a first D2-2 homolog but which does not specifically bind a different D2-2 homolog one can select on the basis of positive binding to the first D2-2 homolog and a lack of binding to the second D2-2 homolog.
- Antibodies specific to a domain of a D2-2 protein are also provided.
- the foregoing antibodies can be used in methods known in the art relating to the localization and activity of the D2-2 protein sequences of the invention, e.g., for imaging these proteins, measuring levels thereof in appropriate physiological samples, in diagnostic methods, etc.
- anti-D2-2 antibodies and fragments thereof containing the binding domain are Therapeutics.
- D2-2 protein may be used to generate activated immune cells that immunospecifically bind a portion of D2-2 and are useful to produce an immunotherapeutic growth inhibiting response against a primary or metastatic tumor expressing D2-2.
- activated immune cells include but are not limited to dendritic cells and cytotoxic T-cells.
- a D2-2 protein or peptide provided by the invention that has an HLA-A2 + motif, e.g., SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, can be used to generate activated immune cells.
- Dendritic cells are known to be the primary type of antigen-presenting cell and addition of such a protein or peptide to dendritic cells by exposing them to the protein or peptide enables the dendritic cell to activate cytotoxic T-cells specific for the peptide (See generally, Tjoa et al., 1996, Prostate 28:65-59).
- Such activated dendritic cells HLA matched to the recipient
- can be used as a Therapeutic see Section 5.11 that targets and kills tumor cells.
- a protein or peptide provided by the invention, that has an HLA-A2+ motif can be used to activate cytotoxic T-cells (HLA matched to the recipient) in vitro.
- Such activated T-cells can be used as a Therapeutic (see Section 5.11) that targets and kills tumor cells.
- the invention further relates to D2-2 proteins, and derivatives (including but not limited to fragments) and analogs of D2-2 proteins.
- Nucleic acids encoding D2-2 protein derivatives and protein analogs are also provided.
- the D2-2 proteins are encoded by the D2-2 nucleic acids described in Section 5.1 supra.
- the proteins, derivatives, or analogs are of D2-2 proteins of animals, e.g., fly, frog, mouse, rat, pig, cow, dog, monkey, human, or of plants.
- the derivative or analog is functionally active, i.e., capable of exhibiting one or more functional activities associated with a full-length, wild-type D2-2 protein.
- such derivatives or analogs which have the desired immunogenicity or antigenicity can be used, for example, in immunoassays, for immunization, for inhibition of D2-2 activity, etc.
- Derivatives or analogs that retain, or alternatively lack or inhibit, a desired D2-2 property of interest e.g., binding to D2-2 binding partner, promotion of cell proliferation
- a specific embodiment relates to a D2-2 fragment that can be bound by an anti-D2-2 antibody.
- Derivatives or analogs of D2-2 can be tested for the desired activity by procedures known in the art, including but not limited to the assays described in Sections 5.7 and 5.9.
- D2-2 derivatives can be made by altering D2-2 sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a D2-2 gene may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of D2-2 genes which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change.
- the D2-2 derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a D2-2 protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change.
- one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
- Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
- the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
- the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
- the positively charged (basic) amino acids include arginine, lysine and histidine.
- the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- proteins consisting of or comprising a fragment of a D2-2 protein consisting of at least 10 (continuous) amino acids of the D2-2 protein is provided.
- the fragment consists of at least 20 or 50 amino acids of the D2-2 protein.
- such fragments are not larger than 35, 100 or 200 amino acids.
- Derivatives or analogs of D2-2 include but are not limited to those molecules comprising regions that are substantially homologous to D2-2 or fragments thereof (e.g., in various embodiments, at least 60% or 70% or 80% or 90% or 95% identity over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art) or whose encoding nucleic acid is capable of hybridizing to a coding D2-2 sequence, under stringent, moderately stringent, or nonstringent conditions.
- the D2-2 derivatives and analogs of the invention can be produced by various methods known in the art.
- the manipulations which result in their production can occur at the gene or protein level.
- the cloned D2-2 gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
- the sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated in vitro.
- the D2-2-encoding nucleic acid sequence can be mutated in vitro or in vivo, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification.
- Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, in vitro site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem 253:6551), use of TAB® linkers (Pharmacia), etc.
- Manipulations of the D2-2 sequence may also be made at the protein level. Included within the scope of the invention are D2-2 protein fragments or other derivatives or analogs which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc.
- analogs and derivatives of D2-2 can be chemically synthesized.
- a peptide corresponding to a portion of a D2-2 protein which comprises the desired domain can be synthesized by use of a peptide synthesizer.
- nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the D2-2 sequence.
- Nonclassical amino acids include but are not limited to the D-isomers of the common amino acids, ⁇ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, ⁇ -Abu, ⁇ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, ⁇ -alanine, fluoro-amino acids, designer amino acids such as ⁇ -methyl amino acids, C ⁇ -methyl amino acids, N ⁇ -methyl amino acids, and amino acid analogs in general.
- the amino acid can be D (dextrorotary) or L (levorotary).
- the D2-2 derivative is a chimeric, or fusion, protein comprising a D2-2 protein or fragment thereof (preferably consisting of at least a domain or motif of the D2-2 protein, or at least 10 amino acids of the D2-2 protein) joined at its amino- or carboxy-terminus via a peptide bond to an amino acid sequence of a different protein.
- a chimeric protein is produced by recombinant expression of a nucleic acid encoding the protein (comprising a D2-2-coding sequence joined in-frame to a coding sequence for a different protein).
- Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.
- a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer.
- Chimeric genes comprising portions of D2-2 fused to any heterologous protein-encoding sequences may be constructed.
- a specific embodiment relates to a chimeric protein comprising a fragment of D2-2 of at least six amino acids.
- the D2-2 derivative is a molecule comprising a region of homology with a D2-2 protein.
- a first protein region can be considered "homologous" to a second protein region when the amino acid sequence of the first region is at least 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 95% identical, when compared to any sequence in the second region of an equal number of amino acids as the number contained in the first region or when compared to an aligned sequence of the second region that has been aligned by a computer homology program known in the art.
- a molecule can comprise one or more regions homologous to a D2-2 domain (see Section 5.6.1) or a portion thereof.
- the invention relates to D2-2 derivatives and analogs, in particular D2-2 fragments and derivatives of such fragments, that comprise, or alternatively consist of, one or more domains of a D2-2 protein, including but not limited to SEQ ID NO: 7, amino acid sequences of D2-2 that contain an HLA-A2 + motif e.g. SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, functional (e.g., binding) fragments of any of the foregoing, or any combination of the foregoing.
- SEQ ID NO: 7 amino acid sequences of D2-2 that contain an HLA-A2 + motif e.g. SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, functional (e.g., binding) fragments of any of the foregoing, or any combination of the foregoing.
- HLA-A2 + motif e.g. SEQ ID NO: 15
- SEQ ID NO: 17 amino acid sequences of D2-2 that contain an HLA-A2 + motif e.g. S
- a specific embodiment relates to molecules comprising specific fragments of D2-2 that are those fragments in the respective D2-2 protein most homologous to specific fragments of a human or other primate D2-2 protein.
- a fragment comprising a domain of a D2-2 homolog can be identified by protein analysis methods as described in Sections 5.3.2 or 6.
- a molecule in another specific embodiment, comprises one or more domains (or functional portion thereof) of a D2-2 protein but that also lacks one or more domains (or functional portion thereof) of a D2-2 protein. In another embodiment, a molecule is provided that comprises one or more domains (or functional portion thereof) of a D2-2 protein, and that has one or more mutant (e.g., due to deletion or point mutation(s)) domains of a D2-2 protein (e.g., such that the mutant domain has decreased function).
- mutant e.g., due to deletion or point mutation(s) domains of a D2-2 protein
- D2-2 proteins, derivatives and analogs can be assayed by various methods.
- various immunoassays known in the art can be used, including but not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc.
- antibody binding is detected by detecting a label on the primary antibody.
- the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody.
- the secondary antibody is labelled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.
- the binding can be assayed, e.g., by means well-known in the art.
- physiological correlates of D2-2 binding t o its substrates can be assayed.
- D2-2 proteins, analogs, derivatives, and subsequences thereof, D2-2 nucleic acids (and sequences complementary thereto), anti-D2-2 antibodies have uses in diagnostics.
- Such molecules can be used in assays, such as immunoassays, to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting D2-2 expression, or monitor the treatment thereof.
- immunoassay is carried out by a method comprising contacting a sample derived from a patient with an anti-D2-2 antibody under conditions such that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody.
- such binding of antibody, in tissue sections can be used to detect aberrant D2-2 localization or aberrant (e.g., high, low or absent) levels of D2-2.
- antibody to D2-2 can be used to assay in a patient tissue or serum sample for the presence of D2-2 where an aberrant level of D2-2 is an indication of a diseased condition.
- aberrant levels i s meant increased or decreased levels relative to that present, or a standard level representing that present, in an analogous sample from a portion of the body or from a subject not having the disorder.
- antibody to D2-2 can be used to assay and screen tissues or bodily fluids including but not limited to spinal fluid and brain tissue for elevated levels of D2-2 expression indicative of a tumor.
- the immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.
- competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric
- D2-2 genes and related nucleic acid sequences and subsequences, including complementary sequences, can also be used in hybridization assays.
- D2-2 nucleic acid sequences, or subsequences thereof comprising about at least 8 nucleotides, can be used as hybridization probes.
- Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with aberrant changes in D2-2 expression and/or activity as described supra.
- such a hybridization assay is carried out by a method comprising contacting a sample containing nucleic acid with a nucleic acid probe capable of hybridizing to D2-2 DNA or RNA, under conditions such that hybridization can occur, and detecting or measuring any resulting hybridization.
- diseases and disorders involving overproliferation of cells can be diagnosed, or their suspected presence can be screened for, or a predisposition to develop such disorders can be detected, by detecting increased levels of D2-2 protein, D2-2 RNA, or D2-2 functional activity or by detecting mutations in D2-2 RNA, DNA or protein (e.g., translocations in D2-2 nucleic acids, truncations in the D2-2 gene or protein, changes in nucleotide or amino acid sequence relative to wild-type D2-2) that cause increased expression or activity of D2-2.
- diseases and disorders include but are not limited to those tumors or tissue types mentioned in Section 6 in which D2-2 is overexpressed.
- levels of D2-2 protein can be detected by immunoassay
- levels of D2-2 RNA can be detected by hybridization assays (e.g., Northern blots, dot blots)
- translocations and point mutations in D2-2 nucleic acids can be detected by Southern blotting, RFLP analysis, PCR using primers that preferably generate a fragment spanning at least most of the D2-2 gene, sequencing of the D2-2 genomic DNA or cDNA obtained from the patient, etc.
- levels of D2-2 mRNA or protein in a patient sample are detected or measured, in which increased levels indicate that the subject has, or has a predisposition to developing, a malignancy or hyperproliferative disorder; in which the increased levels are relative to the levels present in an analogous sample from a portion of the body or from a subject not having the malignancy or hyperproliferative disorder, as the case may be.
- diseases and disorders involving a deficiency in cell proliferation or in which cell proliferation is desirable for treatment are diagnosed, or their suspected presence can be screened for, or a predisposition to develop such disorders can be detected, by detecting decreased levels of D2-2 protein, D2-2 RNA, or D2-2 functional activity, or by detecting mutations in D2-2 RNA, DNA or protein (e.g., translocations in D2-2 nucleic acids, truncations in the gene or protein, changes in nucleotide or amino acid sequence relative to wild-type D2-2) that cause decreased expression or activity of D2-2.
- diseases and disorders include but are not limited to those tumors and tissue types mentioned in Section 6 and its subsections in which D2-2 is overexpressed.
- levels of D2-2 protein, levels of D2-2 RNA, D2-2 binding activity, and the presence of translocations or point mutations can be determined as described above.
- levels of D2-2 mRNA or protein in a patient sample are detected or measured, in which decreased levels indicate that the subject has, or has a predisposition to developing, a malignancy or hyperproliferative disorder; in which the decreased levels are relative to the levels present in an analogous sample from a portion of the body or from a subject not having the malignancy or hyperproliferative disorder, as the case may be.
- Kits for diagnostic use comprise in one or more containers an anti-D2-2 antibody, and, optionally, a labeled binding partner to the antibody.
- the anti-D2-2 antibody can be labeled (with a detectable marker, e.g., a chemiluminescent, enzymatic, fluorescent, or radioactive moiety).
- a kit is also provided that comprises in one or more containers a nucleic acid probe capable of hybridizing to D2-2 RNA.
- a kit can comprise in one or more containers a pair of primers (e.g., each in the size range of 6-30 nucleotides) that are capable of priming amplification e.g., by polymerase chain reaction (see e.g., Innis et al., 1990, PCR Protocols, Academic Press, Inc., San Diego, Calif.), ligase chain reaction (see EP 320,308) use of Q ⁇ replicase, cyclic probe reaction, or other methods known in the art! under appropriate reaction conditions of at least a portion of a D2-2 nucleic acid.
- a kit can optionally further comprise in a container a predetermined amount of a purified D2-2 protein or nucleic acid, e.g., for use as a standard or control.
- the invention provides for treatment or prevention of various diseases and disorders by administration of a therapeutic compound (termed herein "Therapeutic”).
- a therapeutic compound include but are not limited to: D2-2 proteins and analogs and derivatives (including fragments) thereof (e.g., as described hereinabove); antibodies thereto (as described hereinabove); nucleic acids encoding the D2-2 proteins, analogs, or derivatives (e.g., as described hereinabove); D2-2 antisense nucleic acids, and D2-2 agonists and antagonists.
- disorders involving tumorigenesis or cell overproliferation are treated or prevented by administration of a Therapeutic that antagonizes D2-2 function.
- Disorders in which cell proliferation is deficient or is desired are treated or prevented by administration of a Therapeutic that promotes D2-2 function. See details in the subsections below.
- a human D2-2 protein, derivative, or analog, or nucleic acid, or an antibody to a human D2-2 protein is therapeutically or prophylactically administered to a human patient.
- a Therapeutic that antagonizes (i.e., inhibits) D2-2 function.
- examples of such a Therapeutic include but are not limited to D2-2 antibodies, D2-2 antisense nucleic acids, derivatives, or analogs that are functionally active, particularly that are active in inhibiting cell proliferation (e.g., as demonstrated in in vitro assays or in animal models or in Drosophila).
- Other Therapeutics that can be used, e.g., D2-2 antagonists can be identified using in vitro assays or animal models, examples of which are described infra.
- Therapeutics that inhibit D2-2 function are administered therapeutically (including prophylactically): (1) in diseases or disorders involving an increased (relative to normal or desired) level of D2-2 protein or function, for example, in patients where D2-2 protein is overexpressed, genetically defective, or biologically hyperactive; or (2) in diseases or disorders wherein in vitro (or in vivo) assays (see infra) indicate the utility of D2-2 antagonist administration.
- the increased level in D2-2 protein or function can be readily detected, e.g., by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or protein levels, structure and/or activity of the expressed D2-2 RNA or protein.
- D2-2 protein e.g., Western blot, immunoprecipitation followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunocytochemistry, etc.
- hybridization assays to detect D2-2 expression by detecting and/or visualizing D2-2 mRNA (e.g., Northern assays, dot blots, in situ hybridization, etc.), etc.
- Diseases and disorders involving cell overproliferation that can be treated or prevented include but are not limited to malignancies, premalignant conditions (e.g., hyperplasia, metaplasia, dysplasia), benign tumors, hyperproliferative disorders, benign dysproliferative disorders, etc. Examples of these are detailed below.
- Malignancies and related disorders that can be treated or prevented by administration of a Therapeutic that inhibits D2-2 function include but are not limited to those listed in Table 1 (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia).
- malignancy or dysproliferative changes are treated or prevented in the brain, breast, colon, prostate, lung, or skin.
- carcinoma, melanoma, or leukemia is treated or prevented.
- the Therapeutics of the invention that antagonize D2-2 activity can also be administered to treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders listed in Table 1.
- Such prophylactic or therapeutic use is indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp.
- Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function.
- endometrial hyperplasia often precedes endometrial cancer.
- Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplasia can occur in epithelial or connective tissue cells.
- Atypical metaplasia involves a somewhat disorderly metaplastic epithelium.
- Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells.
- Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder.
- the presence of one or more characteristics of a transformed phenotype, or of a malignant phenotype, displayed in vivo or displayed in vitro by a cell sample from a patient can indicate the desirability of prophylactic/therapeutic administration of a Therapeutic that inhibits D2-2 function.
- characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton cell surface protein, etc. (see also id., at pp. 84-90 for characteristics associated with a transformed or malignant phenotype).
- leukoplakia a benign-appearing hyperplastic or dysplastic lesion of the epithelium, or Bowen's disease, a carcinoma in situ, are preneoplastic lesions indicative of the desirability of prophylactic intervention.
- fibrocystic disease cystic hyperplasia, mammary dysplasia, particularly adenosis (benign epithelial hyperplasia) is indicative of the desirability of prophylactic intervention.
- a patient which exhibits one or more of the following predisposing factors for malignancy is treated by administration of an effective amount of a Therapeutic: a chromosomal translocation associated with a malignancy (e.g., the Philadelphia chromosome for chronic myelogenous leukemia, t(14;18) for follicular lymphoma, etc.), familial polyposis or Gardner's syndrome (possible forerunners of colon cancer), benign monoclonal gammopathy (a possible forerunner of multiple myeloma), and a first degree kinship with persons having a cancer or precancerous disease showing a Mendelian (genetic) inheritance pattern (e.g., familial polyposis of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis, medullary thyroid carcinoma with amyloid production and pheochromocytoma, Peutz-Jeghers syndrome, neurofibromatosis of a malign
- a Therapeutic of the invention is administered to a human patient to prevent progression to brain, breast, colon, prostate, lung, or skin.
- carcinoma, melanoma, or leukemia is treated or prevented.
- anti-sense nucleic acids complementary to a sequence encoding a D2-2 protein or functional derivative thereof are administered to inhibit D2-2 function, by way of gene therapy.
- Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject.
- the antisense nucleic acid mediates a therapeutic effect by inhibiting D2-2 transcription and translation.
- the Therapeutic comprises an D2-2 sense or antisense nucleic acid that is part of an expression vector that expresses a D2-2 protein or fragment or chimeric protein thereof in a suitable host.
- a nucleic acid has a promoter operably linked to the D2-2 coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific.
- a nucleic acid molecule is used in which the D2-2 coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the D2-2 nucleic acid (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).
- Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.
- the nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product.
- This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or other viral vector (see U.S. Pat. No.
- microparticle bombardment e.g., a gene gun; Biolistic, Dupont
- coating lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432) (which can be used to target cell types specifically expressing the receptors), etc.
- a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation.
- the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180 dated Apr. 16, 1992 (Wu et al.); WO 92/22635 dated Dec. 23, 1992 (Wilson et al.); WO92/20316 dated Nov. 26, 1992 (Findeis et al.); WO93/14188 dated Jul.
- nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).
- a viral vector that contains the D2-2 nucleic acid is used.
- a retroviral vector can be used (see Miller et al., 1993, Meth. Enzymol. 217:581-599). These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA.
- the D2-2 nucleic acid to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a patient.
- retroviral vectors More detail about retroviral vectors can be found in Boesen et al., 1994, Biotherapy 6:291-302, which describes the use of a retroviral vector to deliver the mdr1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy.
- Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., 1994, J. Clin. Invest. 93:644-651; Kiem et al., 1994, Blood 83:1467-1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114.
- Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development 3:499-503 present a review of adenovirus-based gene therapy.
- Adeno-associated virus has also been proposed for use in gene therapy (Walsh et al., 1993, Proc. Soc. Exp. Biol. Med. 204:289-300.
- Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection.
- the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.
- the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell.
- introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc.
- Numerous techniques are known in the art for the introduction of foreign genes into cells (see e.g., Loeffler and Behr, 1993, Meth. Enzymol. 217:599-618; Cohen et al., 1993, Meth. Enzymol.
- the technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.
- the resulting recombinant cells can be delivered to a patient by various methods known in the art.
- epithelial cells are injected, e.g., subcutaneously.
- recombinant skin cells may be applied as a skin graft onto the patient.
- Recombinant blood cells e.g., hematopoietic stem or progenitor cells
- the amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.
- Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.
- the cell used for gene therapy is autologous to the patient.
- a D2-2 nucleic acid is introduced into the cells such that it is expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect.
- stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention.
- Such stem cells include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells (PCT Publication WO 94/08598, dated Apr. 28, 1994), and neural stem cells (Stemple and Anderson, 1992, Cell 71:973-985).
- Epithelial stem cells (ESCs) or keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures (Rheinwald, 1980, Meth. Cell Bio. 21A:229) . In stratified epithelial tissue such as the skin, renewal occurs by mitosis of stem cells within the germinal layer, the layer closest to the basal lamina. Stem cells within the lining of the gut provide for a rapid renewal rate of this tissue.
- ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture (Rheinwald, 1980, Meth. Cell Bio. 21A:229; Pittelkow and Scott, 1986, Mayo Clinic Proc. 61:771). If the ESCs are provided by a donor, a method for suppression of host versus graft reactivity (e.g., irradiation, drug or antibody administration to promote moderate immunosuppression) can also be used.
- HSC hematopoietic stem cells
- any technique which provides for the isolation, propagation, and maintenance in vitro of HSC can be used in this embodiment of the invention.
- Techniques by which this may be accomplished include (a) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor, or (b) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic.
- Non-autologous HSC are used preferably in conjunction with a method of suppressing transplantation immune reactions of the future host/patient.
- human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration (see, e.g., Kodo et al., 1984, J. Clin. Invest. 73:1377-1384).
- the HSCs can be made highly enriched or in substantially pure form. This enrichment can be accomplished before, during, or after long-term culturing, and can be done by any techniques known in the art. Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified Dexter cell culture techniques (Dexter et al., 1977, J. Cell Physiol. 91:335) or Witlock-Witte culture techniques (Witlock and Witte, 1982, Proc. Natl. Acad. Sci. USA 79:3608-3612).
- the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.
- Therapeutics that can be used include but are not limited to anti-D2-2 antibodies (and fragments and derivatives thereof containing the binding region thereof), D2-2 antisense nucleic acids, and D2-2 nucleic acids that are dysfunctional (e.g., due to a heterologous (non-D2-2 sequence) insertion within the D2-2 coding sequence) that are used to "knockout" endogenous D2-2 function by homologous recombination (see, e.g., Capecchi, 1989, Science 244:1288-1292).
- a nucleic acid containing a portion of a D2-2 gene in which D2-2 sequences flank (are both 5' and 3' to) a different gene sequence is used, as a D2-2 antagonist, to promote D2-2 inactivation by homologous recombination (see also Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).
- D2-2 function can be identified by use of known convenient in vitro assays, e.g., based on their ability to inhibit binding of D2-2 to another protein or inhibit any known D2-2 function, as preferably assayed in vitro or in cell culture, although genetic assays in Drosophila or another species may also be employed.
- suitable in vitro or in vivo assays are utilized to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.
- Therapeutics that inhibit D2-2 function are administered therapeutically (including prophylactically): (1) in diseases or disorders involving an increased (relative to normal or desired) level of D2-2 protein or function, for example, in patients where D2-2 protein is overactive or overexpressed; or (2) in diseases or disorders wherein in vitro (or in vivo) assays (see infra) indicate the utility of D2-2 antagonist administration.
- the increased levels in D2-2 protein or function can be readily detected, e.g., by quantifying protein and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or protein levels, structure and/or activity of the expressed D2-2 RNA or protein.
- D2-2 protein e.g., Western blot, immunoprecipitation followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunocytochemistry, etc.
- hybridization assays to detect D2-2 expression by detecting and/or visualizing respectively D2-2 mRNA (e.g., Northern assays, dot blots, in situ hybridization, etc.), etc.
- chemical mutagenesis, or homologous recombination with an insertionally inactivated D2-2 gene can be carried out to reduce or destroy endogenous D2-2 function, in order to decrease cell proliferation.
- Suitable methods, modes of administration and compositions, that can be used to inhibit D2-2 function are described in Sections 5.8.2 through 5.8.2.1.2, above.
- a Therapeutic that inhibits D2-2 activity is used to treat or prevent hyperproliferative or benign dysproliferative disorders.
- Specific embodiments are directed to treatment or prevention of cirrhosis of the liver (a condition in which scarring has overtaken normal liver regeneration processes), treatment of keloid (hypertrophic scar) formation (disfiguring of the skin in which the scarring process interferes with normal renewal), psoriasis (a common skin condition characterized by excessive proliferation of the skin and delay in proper cell fate determination), benign tumors, fibrocystic conditions, and tissue hypertrophy (e.g., prostatic hyperplasia).
- D2-2 function is inhibited by use of D2-2 antisense nucleic acids.
- the present invention provides the therapeutic or prophylactic use of nucleic acids of at least six nucleotides that are antisense to a gene or cDNA encoding D2-2 or a portion thereof.
- a D2-2 "antisense" nucleic acid as used herein refers to a nucleic acid capable of hybridizing to a portion of a D2-2 RNA (preferably mRNA) by virtue of some sequence complementarity.
- the antisense nucleic acid may be complementary to a coding and/or noncoding region of a D2-2 mRNA.
- Such antisense nucleic acids have utility as Therapeutics that inhibits D2-2 function, and can be used in the treatment or prevention of disorders as described supra in Section 5.8.2 and its subsections.
- the antisense nucleic acids of the invention can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered to a cell, or which can be produced intracellularly by transcription of exogenous, introduced sequences.
- the D2-2 antisense nucleic acids provided by the instant invention can be used to prevent tumors or other forms of aberrant cell proliferation.
- the invention further provides pharmaceutical compositions comprising an effective amount of the D2-2 antisense nucleic acids of the invention in a pharmaceutically acceptable carrier, as described infra.
- the invention is directed to methods for inhibiting the expression of a D2-2 nucleic acid sequence in a prokaryotic or eukaryotic cell comprising providing the cell with an effective amount of a composition comprising an D2-2 antisense nucleic acid of the invention.
- the D2-2 antisense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6 to about 50 oligonucleotides).
- the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides.
- the oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded.
- the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone.
- the oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO 88/09810, published Dec. 15, 1988) or blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134, published Apr.
- hybridization-triggered cleavage agents see, e.g., Krol et al., 1988, BioTechniques 6:958-976
- intercalating agents see, e.g., Zon, 1988, Pharm. Res. 5:539-549.
- a D2-2 antisense oligonucleotide is provided, preferably of single-stranded DNA.
- the oligonucleotide may be modified at any position on its structure with substituents generally known in the art.
- the D2-2 antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosyl
- the oligonucleotide comprises at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.
- the oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.
- the oligonucleotide is an ⁇ -anomeric oligonucleotide.
- An ⁇ -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641).
- the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
- Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.).
- an automated DNA synthesizer such as are commercially available from Biosearch, Applied Biosystems, etc.
- phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209)
- methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.
- the D2-2 antisense oligonucleotide comprises catalytic RNA, or a ribozyme (see, e.g., PCT International Publication WO 90/11364, published Oct. 4, 1990; Sarver et al., 1990, Science 247:1222-1225).
- the oligonucleotide is a 2'-0-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analog (Inoue et al., 1987, FEBS Lett. 215:327-330).
- the D2-2 antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence.
- a vector can be introduced in vivo such that it is taken up by a cell, within which cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention.
- RNA antisense nucleic acid
- Such a vector would contain a sequence encoding the D2-2 antisense nucleic acid.
- Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.
- Such vectors can be constructed by recombinant DNA technology methods standard in the art.
- Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells.
- Expression of the sequence encoding the D2-2 antisense RNA can be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible or constitutive.
- Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), etc.
- the antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a D2-2 gene, preferably a human D2-2 gene.
- absolute complementarity although preferred, is not required.
- a sequence "complementary to at least a portion of an RNA,” as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded D2-2 antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed.
- the ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid.
- the longer the hybridizing nucleic acid the more base mismatches with a D2-2 RNA it may contain and still form a stable duplex (or triplex, as the case may be).
- One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.
- the D2-2 antisense nucleic acids can be used to treat (or prevent) disorders of a cell type that expresses, or preferably overexpresses, D2-2.
- a disorder is a growth deficiency.
- a single-stranded DNA antisense D2-2 oligonucleotide is used.
- Cell types which express or overexpress D2-2 RNA can be identified by various methods known in the art. Such methods include but are not limited to hybridization with a D2-2-specific nucleic acid (e.g. by Northern hybridization, dot blot hybridization, in situ hybridization), observing the ability of RNA from the cell type to be translated in vitro into D2-2, immunoassay, etc.
- primary tissue from a patient can be assayed for D2-2 expression prior to treatment, e.g., by immunocytochemistry or in situ hybridization.
- compositions of the invention comprising an effective amount of a D2-2 antisense nucleic acid in a pharmaceutically acceptable carrier, can be administered to a patient having a disease or disorder which is of a type that expresses or overexpresses D2-2 RNA or protein.
- D2-2 antisense nucleic acid which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the antisense cytotoxicity of the tumor type to be treated in vitro, and then in useful animal model systems prior to testing and use in humans.
- compositions comprising D2-2 antisense nucleic acids are administered via liposomes, microparticles, or microcapsules.
- it may be desirable to utilize liposomes targeted via antibodies to specific identifiable tumor antigens Leonetti et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:2448-2451; Renneisen et al., 1990, J. Biol. Chem. 265:16337-16342).
- the Therapeutics of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans.
- in vitro assays which can be used to determine whether administration of a specific Therapeutic is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a Therapeutic, and the effect of such Therapeutic upon the tissue sample is observed.
- a sample of cells from such malignancy is plated out or grown in culture, and the cells are then exposed to a Therapeutic.
- a Therapeutic which inhibits survival or growth of the malignant cells is selected for therapeutic use in vivo.
- cell proliferation can be assayed by measuring 3 H-thymidine incorporation, by direct cell count, by detecting changes in transcriptional activity of known genes such as proto-oncogenes (e.g., fos, myc) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, etc.
- proto-oncogenes e.g., fos, myc
- cell cycle markers e.g., cell cycle markers
- cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, etc.
- a Therapeutic is indicated for use which exhibits the desired effect, inhibition or promotion of cell growth, upon a patient cell sample from tissue having or suspected of having a hyper- or hypoproliferative disorder, respectively.
- hyper- or hypoproliferative disorders include but are not limited to those described in Sections 5.9.1 through 5.9.3 supra.
- a Therapeutic is indicated for use in treating cell injury or a degenerative disorder (see Section 5.8.2) which exhibits in vitro promotion of growth/proliferation of cells of the affected patient type.
- a degenerative disorder see Section 5.8.2.1 for assays that can be used.
- in vitro assays can be carried out with representative cells of cell types involved in a patient's disorder, to determine if a Therapeutic has a desired effect upon such cell types.
- cells of a patient tissue sample suspected of being pre-neoplastic are similarly plated out or grown in vitro, and exposed to a Therapeutic.
- the Therapeutic which results in a cell phenotype that is more normal (i.e., less representative of a pre-neoplastic state, neoplastic state, malignant state, or transformed phenotype) is selected for therapeutic use.
- Many assays standard in the art can be used to assess whether a pre-neoplastic state, neoplastic state, or a transformed or malignant phenotype, is present.
- characteristics associated with a transformed phenotype include a more rounded cell morphology, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, release of proteases such as plasminogen activator, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton surface protein, etc. (see Luria et al., 1978, General Virology, 3d Ed., John Wiley & Sons, New York pp. 436-446).
- the in vitro assays described supra can be carried out using a cell line, rather than a cell sample derived from the specific patient to be treated, in which the cell line is derived from or displays characteristic(s) associated with the malignant, neoplastic or pre-neoplastic disorder desired to be treated or prevented, or is derived from the cell type upon which an effect is desired, according to the present invention.
- Compounds for use in therapy can be tested in suitable animal model systems prior to testing in humans, including but not limited to rats, mice, chicken, cows, monkeys, rabbits, etc.
- suitable animal model systems prior to testing in humans, including but not limited to rats, mice, chicken, cows, monkeys, rabbits, etc.
- any animal model system known in the art may be used.
- the invention provides methods of treatment (and prophylaxis) by administration to a subject of an effective amount of a Therapeutic of the invention.
- the Therapeutic is substantially purified.
- the subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human. In a specific embodiment, a non-human mammal is the subject.
- Formulations and methods of administration that can be employed when the Therapeutic comprises a nucleic acid are described in Sections 5.9.1.4 and 5.9.2.2 above; additional appropriate formulations and routes of administration can be selected from among those described hereinbelow.
- a Therapeutic of the invention e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the Therapeutic, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a Therapeutic nucleic acid as part of a retroviral or other vector, etc.
- Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
- the compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
- epithelial or mucocutaneous linings e.g., oral mucosa, rectal and intestinal mucosa, etc.
- Administration can be systemic or local.
- a Therapeutic of the invention into the central nervous system by any suitable route, including, but not limited to intraventricular and intrathecal injection.
- Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
- Agents which enhance the delivery of chemotherapeutics to brain tumors such as agonists which activate specific receptors on endothelial cells which regulate permeability, including, e.g., bradykinin agonists (see, e.g., Elliott, et al., 1996, Cancer Research 56:3998-4005) tumor angiogenesis factors (Cserr and Knopf, 1992, Immunol Today 12:507-512) etc. can be used in formulations and methods of administration when the Therapeutic is intended for delivery to a tumor of the central nervous system.
- injection into spinal fluid, and/or procedures utilizing an Ommaya reservoir can be used to introduce a therapeutic of the invention such as an anti-D2-2 antibody, e.g. a bispecific anti-D2-2 antibody, directly into the central nervous system for immunotherapy of a tumor.
- a therapeutic of the invention such as an anti-D2-2 antibody, e.g. a bispecific anti-D2-2 antibody, directly into the central nervous system for immunotherapy of a tumor.
- an anti-D2-2 antibody e.g. a bispecific anti-D2-2 antibody, is employed as a Therapeutic in an immunotherapeutic treatment of a non-brain tumor and is infused into a recipient intravenously.
- Immune cells e.g. dendritic cells or cytotoxic T-cells
- activated dendritic cells HLA-matched to the recipient
- D2-2 protein a D2-2 protein, analog or derivative thereof
- activated cytotoxic T-cells HLA-matched to the recipient
- a D2-2 protein, analog, or derivative thereof are infused into a recipient under conditions that permit their crossing the blood-brain barrier.
- a Therapeutic of the invention e.g., activated dendritic cells that have been exposed to a D2-2 protein, analog or derivative thereof, or activated cytotoxic T-cells that have been exposed ex vivo dendritic cells that have been exposed to a D2-2 protein, analog, or derivative thereof, is administered for the treatment of a non-brain tumor.
- Pulmonary administration of a Therapeutic can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
- administer the Therapeutic of the invention may be desirable to administer the Therapeutic of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
- administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.
- the Therapeutic can be delivered in a vesicle, in particular a liposome (see Langer, 1990 Science 249:1527-1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.)
- the Therapeutic can be delivered in a controlled release system.
- a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng.
- polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al., 1985 Science 228:190; During et al., 1989 Ann. Neurol.
- a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).
- the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Pat. No.
- a nucleic acid Therapeutic can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.
- compositions comprise a therapeutically effective amount of a Therapeutic, and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- Water is a preferred carrier when the pharmaceutical composition is administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
- the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
- Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.
- Such compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
- the formulation should suit the mode of administration.
- the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
- composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- the Therapeutics of the invention can be formulated as neutral or salt forms.
- Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
- the amount of the Therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques.
- in vitro assays may optionally be employed to help identify optimal dosage ranges.
- the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.
- suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight.
- Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight.
- Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.
- the invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
- Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
- Diseases and disorders involving decreased cell proliferation or in which cell proliferation is desired for treatment or prevention, and that can be treated or prevented by promoting D2-2 function include but are not limited to degenerative disorders, growth deficiencies, hypoproliferative disorders, physical trauma, lesions, and wounds; for example, to promote wound healing, or to promote regeneration in degenerated, lesioned or injured tissues, etc.
- nervous system disorders are treated.
- a disorder that is not of the nervous system is treated.
- Lesions which may be treated according to the present invention include but are not limited to the following lesions:
- ischemic lesions in which a lack of oxygen results in cell injury or death, e.g., myocardial or cerebral infarction or ischemia, or spinal cord infarction or ischemia;
- infectious lesions in which tissue is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis;
- degenerative lesions in which tissue is destroyed or injured as a result of a degenerative process, including but not limited to nervous system degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis;
- lesions associated with nutritional diseases or disorders in which tissue is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration;
- lesions associated with systemic diseases including but not limited to diabetes or systemic lupus erythematosus;
- demyelinated lesions of the nervous system in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.
- Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include but are not limited to the lesions of either the central (including spinal cord, brain) or peripheral nervous systems.
- Therapeutics which are useful according to this embodiment of the invention for treatment of a disorder may be selected by testing for biological activity in promoting the survival or differentiation of cells (see also Section 5.9).
- a Therapeutic which elicits one of the following effects may be useful according to the invention:
- a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or
- Such effects may be measured by any method known in the art.
- increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:17-42); and increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured.
- D2-2 function has utility that is not limited to therapeutic or prophylactic applications.
- D2-2 function can be promoted in order to increase growth of animals (e.g., cows, horses, pigs, goats, deer, chickens) and plants (particularly edible plants, e.g., tomatoes, melons, lettuce, carrots, potatoes, and other vegetables), particularly those that are food or material sources.
- animals e.g., cows, horses, pigs, goats, deer, chickens
- plants particularly edible plants, e.g., tomatoes, melons, lettuce, carrots, potatoes, and other vegetables
- the invention can be used in plants or animals to increase growth where desired (e.g., in the fruit or muscle).
- a D2-2 nucleic acid under the control of a temperature-sensitive promoter can be administered to a plant or animal, and the desired portion of the (or the entire) plant or animal can be subjected to heat in order to induce D2-2 nucleic acid production, resulting in increased D2-2 expression, and resulting cell proliferation.
- Methods to make plants recombinant are commonly known in the art and can be used.
- methods of plant transformation e.g., for transformation with a D2-2 antisense nucleic acid
- methods of targeted gene inactivation in plants e.g., to inactivate D2-2
- Miao and Lam 1995, The Plant J. 7:359-365.
- Promotion of D2-2 function can also have uses in vitro, e.g., to expand cells in vitro, including but not limited to stem cells, progenitor cells, muscle cells, fibroblasts, liver cells, etc., e.g., to grow cells/tissue in vitro prior to administration to a patient (preferably a patient from which the cells were derived), etc.
- D2-2 nucleic acids, proteins, and derivatives also have uses in screening assays to detect molecules that specifically bind to D2-2 nucleic acids, proteins, or derivatives and thus have potential use as agonists or antagonists of D2-2, in particular, molecules that thus affect cell proliferation.
- such assays are performed to screen for molecules with potential utility as anti-cancer drugs or lead compounds for drug development.
- the invention thus provides assays to detect molecules that specifically bind to D2-2 nucleic acids, proteins, or derivatives.
- recombinant cells expressing D2-2 nucleic acids can be used to recombinantly produce D2-2 proteins in these assays, to screen for molecules that bind to a D2-2 protein.
- Molecules e.g., putative binding partners of D2-2
- D2-2 protein or fragment thereof
- Similar methods can be used to screen for molecules that bind to D2-2 derivatives or nucleic acids. Methods that can be used to carry out the foregoing are commonly known in the art.
- diversity libraries such as random or combinatorial peptide or nonpeptide libraries can be screened for molecules that specifically bind to D2-2.
- libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries.
- phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R.B., et al., 1992, J. Mol. Biol. 227:711-718); Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.
- In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.
- a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use.
- Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used.
- Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).
- Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci.
- screening can be conducted out by contacting the library members with a D2-2 protein (or nucleic acid or derivative) immobilized on a solid phase and harvesting those library members that bind to the protein (or nucleic acid or derivative).
- a D2-2 protein or nucleic acid or derivative
- Examples of such screening methods termed “panning” techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited hereinabove.
- the two-hybrid system for selecting interacting proteins in yeast can be used to identify molecules that specifically bind to a D2-2 protein or derivative.
- animal models for diseases and disorders involving cell hypoproliferation are provided.
- Such an animal can be initially produced by promoting homologous recombination between a D2-2 gene in its chromosome and an exogenous D2-2 gene that has been rendered biologically inactive (preferably by insertion of a heterologous sequence, e.g., an antibiotic resistance gene).
- this homologous recombination is carried out by transforming embryo-derived stem (ES) cells with a vector containing the insertionally inactivated D2-2 gene, such that homologous recombination occurs, followed by injecting the ES cells into a blastocyst, and implanting the blastocyst into a foster mother, followed by the birth of the chimeric animal ("knockout animal") in which a D2-2 gene has been inactivated (see Capecchi, 1989, Science 244:1288-1292).
- the chimeric animal can be bred to produce additional knockout animals. Such animals can be mice, hamsters, sheep, pigs, cattle, etc., and are preferably non-human mammals. In a specific embodiment, a knockout mouse is produced.
- Such knockout animals are expected to develop or be predisposed to developing diseases or disorders involving cell hypoproliferation. Such animals can be used to screen for or test molecules for the ability to promote proliferation and thus treat or prevent such diseases and disorders.
- transgenic animals that have incorporated and express a functional D2-2 gene have use as animal models of diseases and disorders involving cell hyperproliferation or malignancy.
- Such animals are expected to develop or be predisposed to developing diseases or disorders involving cell hyperproliferation (e.g., malignancy) and thus can have use as animal models of such diseases and disorders, e.g., to screen for or test molecules (e.g., potential anti-cancer therapeutics) for the ability to inhibit overproliferation (e.g., tumor formation) and thus treat or prevent such diseases or disorders.
- test molecules e.g., potential anti-cancer therapeutics
- GMT glioblastoma multiforme tissue
- NBT normal adult brain tissue
- Brain tumor cell lines CCF-STTG1 (astrocytoma grade IV), SW 1783 (astrocytoma grade III), IMR-32 (neuroblastoma), D283 Med (medulloblastoma), Hs 683 (glioma), PFSK-1 (primitive neuroectodermal tumor) and DBTRG-05MG (glioblastoma multiforme) cell lines were purchased from ATCC (American Type Culture Collection, Rockville, Md.). Fetal normal human astrocytes (FNHA) were purchased from Clonetics (San Diego, Calif.). All the cell lines were cultured under the conditions recommended by ATCC or Clonetics.
- DD-PCR Differential Display--Polymerase Chain Reaction
- DD-15 PCR is a modified PCR technique first developed in 1992 (Liang et al., 1992, Science, 257:967-971; and Liang et al., 1992, Cancer Res., 52:6966-6968). This technique is much more sensitive and reproducible than previously documented techniques of differential hybridization and subtractive library construction.
- DD-PCR technique has been modified and improved to increase PCR specificity and efficiency (Hadman et al., 1995 Anal. Biochem., 226:383-386; Bauer et al., 1993 Nucleic Acids Res., 21:4272-4280).
- NBT Normal brain tissue
- GMT Greenberg-Green Tissue
- NBT and GMT were obtained from the same region of the brain.
- Total RNA was isolated using the GITC/CsCl 2 protocol described previously by Sambrook et al., 1989 Molecular Cloning A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory. Five ⁇ g of total RNA was treated with DNaseI (Amersham, Arlington Heights, Ill.) (2u/ ⁇ l) for 30 minutes at 37° C. RNA was then extracted and precipitated using 3M sodium acetate.
- First strand cDNA synthesis was then carried out using the Advantage 1st Strand cDNA synthesis kit from Clontech (Palo Alto, Calif.) and BT3-2 primer (5'T(T)18NG3'). Approximately 125 ng of first strand cDNA synthesis product was used for carrying out the PCR reaction.
- DD-PCR reaction was carried out using ( ⁇ P 32 )end labelled BT-2 primer and BT-8 (5'NTACTGATCCATGACA3') (SEQ ID NO: 3), BT-10 (5'NGCTGCTCTCATACT3') (SEQ ID NO: 4), or BT-12 (5'NTGATCTAAGGCACATA3') (SEQ ID NO: 5) primers using cDNA from NBT or GMT tissue in duplicate, and using the conditions of Hadman et al., supra. PCR products were then electrophoresed on a 6% sequencing gel. The bands that showed differential expression were then cut out and DNA was eluted. PCR was then carried as done for DD-PCR conditions using appropriate primers.
- PCR product was then cloned into PCRII vector from Invitrogen (San Diego, Calif.). Positive clones were screened by PCR and sequenced using the Sequenase version 2.0 sequencing kit (Amersham/USB, Arlington Heights, Ill.).
- a RT-PCR technique (Ikonomov et al., 1996, Biotechniques, 20:1030-1042) was used.
- 5 ⁇ g of total RNA was treated with DNaseI and first strand synthesis was carried out under the same conditions as described previously.
- First strand cDNA was used as template to carry out PCR using primers BT-41 (5'CTCAGTGTTAACGGATAAT3') (SEQ ID NO: 8) and BT-42 (5'TGTTGAGAAGAGTACATCTT3') (SEQ ID NO: 9) that were specific for D2-2.
- BT-41 5'CTCAGTGTTAACGGATAAT3'
- BT-42 5'TGTTGAGAAGAGTACATCTT3'
- D1-2 which is expressed in both NBT and GMT at the same level, was used as an internal control.
- PCR for D1-2 was carried out using BT-59 (5'CGGAGCAATATGAAATGATCT3') (SEQ ID NO: 10) and BT-60 (5'GCAAATACAGCTCCTATTG3') (SEQ ID NO: 11).
- PCR was carried out using a Gene Amp PCR kit (Perkin-Elmer, Branchburg, Ill.) under the following conditions: 4 ⁇ l of dNTP mix, 2 ⁇ l (100 ng/ ⁇ l) each of D1-2 or D2-2 specific primers, 4 ⁇ l of 25 mM MgCl 2 , 125 ng of cDNA template and 5 units of Amplitaq DNA polymerase.
- PCR conditions were as follows: 94° C., 50° C. and 72° C.
- D1-2 and D2-2 specific probes were prepared by the multiprime labelling (using an Amersham Megaprime Labelling Kit, Arlington Heights, Ill.) of D2-2 specific primers BT-66 (5'CCAAACTGGACATCAAGGAATTGCTACACAGAAGAACCACCATCCAGGATAGAA3') (SEQ ID NO: 12) or D1-2 specific primer BT-69 (5'TAGGCCTGACTGGCATTGTATTAGCAAACTCATCACTAGA3') (SEQ ID NO: 13). These primers are internal to the primers used for PCR and they do not carry any of the primer sequences used in the PCR.
- DD-PCR product for clone D2-2 was about 250 bases long. It had 100% homology to a partial DNA sequence (1.0 kb) in the TIGR (The Institute for Genome Research, Rockville, Md.) database which has no known function or homology to other sequences in the database.
- a partial fragment of D2-2 (an EcoRI and XbaI 750 bp fragment) was used to screen a human brain library from Stratagene (La Jolla, Calif.). One positive clone of 2.0 Kb insert size was isolated. Both strands were sequenced by Sequetech Corporation (Mountain View, Calif.).
- MTB Multiple Tissue Blots
- Clontech Clontech (Palo Alto, Calif.) were used. These blots contained 2 ⁇ g of pure PolyA mRNA blotted. MTBs were prehybridized in express hybridization buffer solution for 3-4 hours. Hybridization was done with multiprime-labelled 750 bp D2-2 probe. After autoradiographic exposure, the probe was washed from the blot and then hybridized with human ⁇ actin probe. Quantitation of expression of D2-2 and ⁇ actin was achieved using the ImageQuaNTTM program of the Molecular Dynamic Phosphor Imager (Sunnyvale, Calif.).
- the Master Blot contained 200 ng of pure polyA RNA blotted onto the membrane. Prehybridization and hybridization was conducted with the 750 bp D2-2 probe as described supra for Northern Blot analysis. To normalize the RNA, the blot was hybridized with human ubiquitin probe. Quantitation of the signal was achieved using the Molecular Dynamic Phosphor Imager.
- the modified DD-PCR technique was used to isolate genes that are differentially expressed either in NBT or GMT as described in Section 6.1.2, supra. Using one 3' primer and three 5' primers, DD-PCR was performed on GMT and NBT. Nineteen bands were isolated that showed differential expression either in GMT or NBT. Fourteen of these bands were expressed at higher levels in GMT and four were is expressed at higher levels in NBT. All of these bands were isolated, and DNA was eluted, reamplified and cloned into the PCRII vector from Invitrogen (San Diego, Calif.).
- D2-2 was found to be overexpressed 55-fold in GMT and 8.5-fold in meningioma tumor tissue (MTT) as compared to NBT (FIGS. 2A-C). D2-2 was detected at very low levels in a B cell lymphoma tumor sample. D1-2, a gene that was isolated from the same DD-PCR and is expressed consistently in normal and tumor samples, was used as an internal control. The results presented in FIGS. 2A-C indicate that D2-2 is differentially expressed in GMT and NBT.
- the D2-2 clone that was isolated by DD-PCR is only 250 base pairs in length and it has a long polyA tail. This clearly indicates that the D2-2 sequence is at the 3' end of the gene. No known identical sequences for D2-2 were found in the National database (NIH, Bethesda, Md.). Conversely, sequence homology analysis of D2-2 with the TIGR (The Institute for Genome Research, Rockville, Md.) database indicated that there was 100% homology to a 1.0 Kb partial cDNA (SEQ ID NO: 14) with no known function, cloned from brain or prostate adenocarcinoma tissue (Gleason score of 9). Since the length of D2-2 isolated from DD-PCR is 250 bp, the rest of the TIGR clone was searched for homologous sequences in the National database (NIH, Bethesda, Md.). No significant homology was found.
- a human fetal brain library was screened. Using this method, one clone was isolated that was about 2.0 Kb in size (SEQ ID NO: 1). This EcoRI-XhoI fragment was sequenced from both the strands and the nucleotide sequence is shown in FIG. 3. Sequence analysis indicated that it has a small ORF (open reading frame) and the deduced amino acid sequence is also shown in FIG. 3. Protein homology analysis of the partial amino acid sequence also demonstrated that there are three HLA-A2 + motifs as represented by SEQ ID NO: 15 (amino acids 8-16), SEQ ID NO: 17 (amino acids 27-35), and SEQ ID NO: 19 (amino acids 56-63).
- the 80 amino acids of the presently taught ORF have no other homology to known proteins in the National database. Except for the presence of 80 amino acids, the majority of the fragment has a 3' untranslated sequence. This indicates that D2-2 is a novel protein. Analysis of the 3' UTR (untranslated region) indicated that there are small stretches of Alu repeat sequences. This analysis demonstrates that D2-2 is a novel gene.
- D2-2 was examined in other tissue samples obtained from the Northwest Hospital Tissue Bank. RT-PCR of D2-2 was performed as described in Section 6.1.3 supra. Dl-2 was used as a control. Results are shown in FIGS. 4A-C.
- D2-2 high levels of expression of D2-2 are observed in glioblastoma, recurrent glioma, colon cancer metastatic to brain, prostate adenocarcinoma (Gleason score of 9) tumors, and the LNCaP (prostate cancer) cell line.
- Moderate to low levels of D2-2 expression were observed in two cases of meningiomas, a diffuse malignant lymphoma of the B cell type and a breast ductal carcinoma as compared to normal brain.
- D2-2 in cell lines derived from different human brain tumors and normal human astrocytes (fetal) was investigated by growing human brain tumor cell lines (glioblastoma, astrocytoma grade III, astrocytoma grade IV, glioma, medulloblastoma, neuroectodermal, neuroblastoma) to 80% confluency. PCR and Southern blot analysis were performed as described in Section 6.1.3., supra. As shown in FIGS. 5A--C, D2-2 is expressed at very high levels in glioblastoma, astrocytoma grade IV, glioma and FNHA. Moderate levels were expressed in neuroectodermal and medulloblastoma brain tumor. These results showed that D2-2 is expressed at high levels in the majority of the brain tumor cell lines investigated.
- D2-2 was studied in several tumor cell lines as described in Section 6.1.5. As shown in FIG. 6A-C, MOLT lymphoblastic leukemia, SW480 colorectal adenocarcinoma, A549 lung carcinoma, HL-60 promyelocytic leukemia, S3 HeLa cells, K-562 chronic myelogenous leukemia and G361 melanoma showed high expression, and Burkitt's lymphoma Raji showed low expression of D2-2 as compare to NBT. These results demonstrate that D2-2 is overexpressed in the majority of the tumor cell lines investigated.
- D2-2 is expressed at high levels in the frontal lobe, occipital lobe and cerebellum.
- D2-2 is expressed at high levels in thyroid, and at moderate levels in pancreas, adrenal cortex, testis, thymus, small intestine, stomach and fetal liver. The remaining tissues expressed D2-2 minimally. It is interesting to note that D2-2 was expressed in much higher levels in tissues of the endocrine system.
- D2-2 has a role in the immune system
- its expression was studied in different organs from the immune system. As shown in FIGS. 8A-C, expression for D2-2 is highest in thymus and fetal liver as compared to lymph node, appendix, peripheral blood leukocytes or bone marrow. The significance of high level of D2-2 expression in normal tissue of selective organs is not known at present.
- oncogenes that are over expressed in tumors, e.g., jun and fos, are also shown to be very highly expressed during early development hence they are termed onco-fetal proteins (Angel and Karin, 1991 Biochem. Biophys. Acta, 1072: 129-157).
- D2-2 also shows a similar expression pattern, the expression of D2-2 was studied in seven fetal (20 weeks) and adult tissues using dot blot analysis as described in section 6.1.6, supra.
- D2-2 is expressed at very high levels in fetal brain and heart as compared to adult brain and heart. Conversely, such a dramatic difference in expression has not been observed with kidney, liver, spleen, lung or thymus. These results indicate that D2-2 may be involved in some function during early development. Although not intending to be limited to any particular explanation, the inventors propose that D2-2 may be an onco-fetal protein.
- oncogenes such as jun and fos are expressed at high levels when cells are proliferating rapidly in a serum-containing media (Angel and Karin, 1991 Biochem. Biophys. Acta, 1072: 129-157). If cells are starved for serum for 48 hours or longer, the majority of cells enter G 0 /G 1 phase of the cell cycle. Not only will these cells will stop proliferation, but expression of these oncogenes also decreases several fold.
- D2-2 The expression of D2-2 in several brain tumor cell lines in culture media containing or lacking serum was studied. The results showed that expression of D2-2 decreases in cells (neuroectodermal, glioblastoma and FNHA) that are starved for serum for 72 hours (data not shown).
- D2-2 Onco-fetal proteins show high expression not only during early development but also in several different tumor types. D2-2 is expressed at very high levels in the brain and heart of 20 week old fetus, but its expression drops to low level in adults. This indicates that D2-2 plays an important role during early brain and heart development.
- D2-2 is overexpressed in glioblastoma multiforme and cell lines derived from other types of brain tumors. It has high expression not only in the GMT tissue from which it was isolated, but also in the majority of non-brain tumor cell lines and tissues examined. With the exception of the promyelocytic leukemia HL-60 and Burkitt's lymphoma Raji cell lines, the majority of tumor cell lines derived from non-brain tissues showed high expression of D2-2. In addition, D2-2 is expressed at high levels in other tumor tissues such as prostate adenocarcinoma (Gleason score of 9), breast ductal carcinoma and LNCaP (prostate tumor cell line) cell lines. This demonstrates that D2-2 is a gene with high expression in a variety of tumors, besides brain tumors.
- Gleason score of 9 prostate adenocarcinoma
- LNCaP prostate tumor cell line
- D2-2 was detected at very low levels in two brain tumor cell lines, i.e., grade III astrocytoma and neuroblastoma cell lines.
- grade III astrocytoma and neuroblastoma cell lines The reason for this low expression is not known at present, however, it is envisaged that such expression patterns can be used for differential detection or diagnosis of brain tumors such as, but not limited to, glioblastoma, astrocytoma, glioma, neuroectodermal, and medulloblastomas.
- the present invention has utility in elucidating the process of tumorigenesis for early detection of brain tumors, including but not limited to highly malignant brain tumors, and provides better strategies for effective treatment of brain tumors.
- E. coli designated NWB-D2-2 containing plasmid D2-2, containing an EcoRI-XhoI 2.0 Kb fragment was deposited on Nov. 5, 1996 with the American Type Culture Collection, 1201 Parklawn Drive, Rockville, Md. 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned Accession No. 98246.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
TABLE 1 ______________________________________ MALIGNANCIES AND RELATED DISORDERS ______________________________________ Leukemia acute leukemia acute lymphocytic leukemia acute lymphoblastic leukemia acute myelocytic leukemia myeloblastic myelogenous promyelocytic myelomonocytic monocytic erythroleukemia chronic leukemia chronic myelocytic (granulocytic) leukemia chronic myelogenous leukemia chronic lymphocytic leukemia Polycythemia vera Lymphoma Hodgkin's disease non-Hodgkin's disease Multiple myeloma Waldenstrom's macroglobulinemia Heavy chain disease Solid tumors sarcomas and carcinomas adenocarcinoma fibrosarcoma myxosarcoma liposarcoma chondrosarcoma osteogenic sarcoma chordoma angiosarcoma endotheliosarcoma lymphangiosarcoma lymphangioendotheliosarcoma synovioma mesothelioma Ewing's tumor leiomyosarcoma rhabdomyosarcoma colon carcinoma colorectal adenocarcinoma colon tumor metastatic to brain lung carcinoma pancreatic cancer breast cancer ovarian cancer prostate cancer squamous cell carcinoma basal cell carcinoma adenocarcinoma sweat gland carcinoma sebaceous gland carcinoma papillary carcinoma papillary adenocarcinomas cystadenocarcinoma medullary carcinoma bronchogenic carcinoma renal cell carcinoma hepatoma bile duct carcinoma choriocarcinoma seminoma embryonal carcinoma Wilms' tumor cervical cancer uterine cancer testicular tumor lung carcinoma small cell lung carcinoma bladder carcinoma epithelial carcinoma glioblastoma glioma astrocytoma medulloblastoma craniopharyngioma ependymoma pinealoma hemangioblastoma acoustic neuroma oligodendroglioma meningioma melanoma neuroblastoma retinoblastoma ______________________________________
__________________________________________________________________________ SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 20 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2002 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: TGCAGGAATTCGGCACGAGGATTGAGTAACTTGCTGTCACTGCTTGTACTTTGTAGACAG60 CCTGAGAGTGGCAGGACCTTATGTGAATGGGGGGGATGGACTGTGATCAGTGCCGGGGAG120 TCTCTGAAGCTGGGGTCCCCACCTCCAGGGGCTTCTGCTCAGAGGTTACGTGTGCAGTTT180 GAAGATGTACATCTTGACCTCCGGTTTAGAGGCACTTTCTGCCCATCAGATTCCAAACTC240 TAGGGGCGCAGCACCTTTTCTTTGCTCCCAAACACCAACCAACACCCCTTCACAGGACCA300 GCACTGTTAGGATGGCTAAGTGGATGTTTTATGTTCCCACGTCCCTGACTCTGTTTCAGA360 GGTTGTGTCTGCTCTCCCAGCCCCTGAAGCCAAAATGACTTCCTGCAGCTTTCATGAGCT420 CAGCCTCTTCCCTGGGGTATGTGTGAGGGGGAAAGCCTGGTTCAAGTTTAGATTTATTTC480 TAGGGAGCCCTGGTTTCTTCATACCAGAGGCTACCCTTAGAACTTTGGAGTGGGGTATCT540 TTTTTTCATTTGTTTTTTTGATACAGAGTCTCGCTCTATTGCCCAGGCTGGAGTGCGGTG600 GCACAATCTCAGCTTACTGCAACCTCCACCTCCAGGGTTCAAGCGATTCTCCTGCCTCAG660 CCTCCCGAGTAGCTGGCATTACAGGCACCTGCCACCACACCCGGCTAAATTTTGTATTTT720 TAGTAGAGAAGGGGTTTCACCATGTTGGTGAGGCTTGTCTCAAACTGACTTCAAGTGATC780 CACTTGCTTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCATCACGCCCAGCCGA840 GGGTATCTTTTATACCAACAAATTAGATGACTGAGGTGTAATGGACAAATCCTATGCACA900 AAGTGAGGGTATCTGAATATGTGGGCGGGAGTCAAAAATTTTTAGCTACTTTAACACTAA960 AGTCAAACTAAAGTAGCTTCAAAAAGACTTCTCAAGATGCAGTATGGCCTGCTGAGGTTT1020 TTTTGTTTTTTTTTTTTTTAAGACAGAGAGTCGCTCGTCGCCCAGGCCGCAGTGCAGTAG1080 CATGATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAGCGATTCTCCTGTCTCAGC1140 CTCCTAAGTAGCTGGGACTACAGGCACCTGCCACCACGCCCATCTAAGTTTTGCATTTTT1200 AGTAGCGACGGTTTCACCTTGTTGGCCAGGCTGGTTTTGTTGGCCAATTGTCTCTAAACT1260 GCTGTCAAAAAAAGGAATGGATCAGATTGTCTTGAATAGGGCAGAGCTAACCTGTAATCA1320 CCTGTGTGATGAGAAACAGCTTTGACTGCATTTTACTCCTGACCTGGCCTAAGCTTTCTG1380 TTTACATAAGATTTTTCAAGAATTCAACTTCAAGTAGCAGCCGAGAGAGCTGCCTCAGGA1440 TTCTCTCAAAAACTGGGAATAATATGGGAACATTTGTTTCTTCTAAAAATAAGGCAAATG1500 TTACATTGAATGATTTGGGGGGTGAGGTTTAATTGGAAATGGTCTCTGGGGACTGAAAAC1560 TGATGTTTTTGCAGATTACCTCAGGGAAACGGAGGTTTGTTGAGTTTACAGACACATTAA1620 ACCAAAGGCCGTGGGAAAACCCCTCTCCAGCTCCAGGGGATTGGTCAGGACCACCCACTA1680 ACCAGTGCCTTCCTTCTTAACATTCACTTTTAGCAGCTTGTGTTTATTTTACATGGGCAG1740 TTTTGATGGGAAATTGCCATGACCACAGGGGTTTGGAGTTCTGCTTTTTTTTTTTCTTCT1800 TCTTTTTCGGGGGACTGGGGGACTCCTCCCAAGATCACATTTTAGCATCTTTCTCTCCTA1860 CTCCATTTAGAAAAATAAGTAACAGGTGAAATGTGGTCTCAGTGTTAACGGGATAATTCT1920 GCTACCGGCTCCTCCCTGATGATTCTGAAATACACTACTGAACGAGCTCTGGCTGGTCCT1980 TTCAAAAAAAAAAAAAAAAAAA2002 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 144 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: TACTCCATTTAGAAAAATAAGTAACAGGTGAAATGTGGTCTCAGTGTTAACGGGATAATT60 CTGCTACCGGCTCCTCCCTGATGATTCTGAAATACACTACTGAACGAGCTCTGGCTGGTC120 CTTTCAAAAAAAAAAAAAAAAAAA144 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 1 (D) OTHER INFORMATION: Where N is any nucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: NTACTGATCCATGACA16 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 1 (D) OTHER INFORMATION: Where N is any nucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: NGCTGCTCTCATACT15 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Modified Base (B) LOCATION: 1 (D) OTHER INFORMATION: Where N is any nucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: NTGATCTAAGGCACATA17 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...240 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: TGCAGGAATTCGGCACGAGGATTGAGTAACTTGCTGTCACTGCTTGTA48 CysArgAsnSerAlaArgGlyLeuSerAsnLeuLeuSerLeuLeuVal 151015 CTTTGTAGACAGCCTGAGAGTGGCAGGACCTTATGTGAATGGGGGGGA96 LeuCysArgGlnProGluSerGlyArgThrLeuCysGluTrpGlyGly 202530 TGGACTGTGATCAGTGCCGGGGAGTCTCTGAAGCTGGGGTCCCCACCT144 TrpThrValIleSerAlaGlyGluSerLeuLysLeuGlySerProPro 354045 CCAGGGGCTTCTGCTCAGAGGTTACGTGTGCAGTTTGAAGATGTACAT192 ProGlyAlaSerAlaGlnArgLeuArgValGlnPheGluAspValHis 505560 CTTGACCTCCGGTTTAGAGGCACTTTCTGCCCATCAGATTCCAAACTCT241 LeuAspLeuArgPheArgGlyThrPheCysProSerAspSerLysLeu 65707580 AG243 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 80 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: CysArgAsnSerAlaArgGlyLeuSerAsnLeuLeuSerLeuLeuVal 151015 LeuCysArgGlnProGluSerGlyArgThrLeuCysGluTrpGlyGly 202530 TrpThrValIleSerAlaGlyGluSerLeuLysLeuGlySerProPro 354045 ProGlyAlaSerAlaGlnArgLeuArgValGlnPheGluAspValHis 505560 LeuAspLeuArgPheArgGlyThrPheCysProSerAspSerLysLeu 65707580 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: CTCAGTGTTAACGGATAAT19 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...243 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: TGTTGAGAAGAGTACATCTT20 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: CGGAGCAATATGAAATGATCT21 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GCAAATACAGCTCCTATTG19 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: CCAAACTGGACATCAAGGAATTGCTACACAGAAGAACCACCATCCAGGATAGAA54 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: TAGGCCTGACTGGCATTGTATTAGCAAACTCATCACTAGA40 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...27 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: TTGAGTAACTTGCTGTCACTGCTTGTA27 LeuSerAsnLeuLeuSerLeuLeuVal 15 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: LeuSerAsnLeuLeuSerLeuLeuVal 15 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...27 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: TTATGTGAATGGGGGGGATGGACTGTG27 LeuCysGluTrpGlyGlyTrpThrVal 15 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: LeuCysGluTrpGlyGlyTrpThrVal 15 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Genomic DNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...24 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: TTACGTGTGCAGTTTGAAGATGTA24 LeuArgValGlnPheGluAspVal 15 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: LeuArgValGlnPheGluAspVal 15 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1000 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: TATGGCCTGCTGAGGTTTTTTTGTTTTTTTTTTTTTTAAGACAGAGAGTCGCTCGTCGCC60 CAGGCCGCAGTGCAGTAGCATGATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAG120 CGATTCTCCTGTCTCAGCCTCCTAAGTAGCTGGGACTACAGGCACCTGCCACCACGCCCA180 TCTAAGTTTTGCATTTTTAGTAGCGACGGTTTCACCTTGTTGGCCAGGCTGGTTTTGTTG240 GCCAATTGTCTCTAAACTGCTGTCAAAAAAAGGAATGGATCAGATTGTCTTGAATAGGGC300 AGAGCTAACCTGTAATCACCTGTGTGATGAGAAACAGCTTTGACTGCATTTTACTCCTGA360 CCTGGCCTAAGCTTTCTGTTTACATAAGATTTTTCAAGAATTCAACTTCAAGTAGCAGCC420 GAGAGAGCTGCCTCAGGATTCTCTCAAAAACTGGGAATAATATGGGAACATTTGTTTCTT480 CTAAAAATAAGGCAAATGTTACATTGAATGATTTGGGGGGTGAGGTTTAATTGGAAATGG540 TCTCTGGGGACTGAAAACTGATGTTTTTGCAGATTACCTCAGGGAAACGGAGGTTTGTTG600 AGTTTACAGACACATTAAACCAAAGGCCGTGGGAAAACCCCTCTCCAGCTCCAGGGGATT660 GGTCAGGACCACCCACTAACCAGTGCCTTCCTTCTTAACATTCACTTTTAGCAGCTTGTG720 TTTATTTTACATGGGCAGTTTTGATGGGAAATTGCCATGACCACAGGGGTTTGGAGTTCT780 GCTTTTTTTTTTTCTTCTTCTTTTTCGGGGGACTGGGGGACTCCTCCCAAGATCACATTT840 TAGCATCTTTCTCTCCTACTCCATTTAGAAAAATAAGTAACAGGTGAAATGTGGTCTCAG900 TGTTAACGGGATAATTCTGCTACCGGCTCCTCCCTGATGATTCTGAAATACACTACTGAA960 CGAGCTCTGGCTGGTCCTTTCAAAAAAAAAAAAAAAAAAA1000 __________________________________________________________________________
Claims (16)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/747,121 US5874290A (en) | 1996-11-08 | 1996-11-08 | Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon |
AU51996/98A AU5199698A (en) | 1996-11-08 | 1997-11-07 | Nucleotide and amino acid sequences of a (d2-2) gene associated with brain tumors and methods based thereon |
PCT/US1997/020410 WO1998019692A1 (en) | 1996-11-08 | 1997-11-07 | Nucleotide and amino acid sequences of a d2-2 gene associated with brain tumors and methods based thereon |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/747,121 US5874290A (en) | 1996-11-08 | 1996-11-08 | Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon |
Publications (1)
Publication Number | Publication Date |
---|---|
US5874290A true US5874290A (en) | 1999-02-23 |
Family
ID=25003727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/747,121 Expired - Lifetime US5874290A (en) | 1996-11-08 | 1996-11-08 | Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon |
Country Status (3)
Country | Link |
---|---|
US (1) | US5874290A (en) |
AU (1) | AU5199698A (en) |
WO (1) | WO1998019692A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164624A1 (en) * | 2001-02-12 | 2002-11-07 | Waldemar Debinski | VEGF-D expression in brain cancer |
WO2004050007A2 (en) * | 2002-11-29 | 2004-06-17 | Develogen Ag | Mammalian bt-42 proteins involved in the regulation of energy homeostasis |
EP1829888A1 (en) | 2000-05-02 | 2007-09-05 | Yale University | Anti-inflammatory compounds and uses thereof |
US20130158113A1 (en) * | 2011-06-10 | 2013-06-20 | Golden Biotechnology Corporation | Methods and compositions for treating brain cancer |
-
1996
- 1996-11-08 US US08/747,121 patent/US5874290A/en not_active Expired - Lifetime
-
1997
- 1997-11-07 WO PCT/US1997/020410 patent/WO1998019692A1/en active Application Filing
- 1997-11-07 AU AU51996/98A patent/AU5199698A/en not_active Abandoned
Non-Patent Citations (40)
Title |
---|
Angel and Karin, 1991, "The Role of Jun, Fos and the AP-1 Complex in Cell-Proliferation and Transformation", Biochem. Biophys. Acta 1072:129-157. |
Angel and Karin, 1991, The Role of Jun, Fos and the AP 1 Complex in Cell Proliferation and Transformation , Biochem. Biophys. Acta 1072:129 157. * |
Bauer, D. et al., 1993, "Identification of Differentially Expressed mRNA Species by an Improved Display Technique (DDRT-PCR)", Nucleic Acids Res. 21:4272-4280. |
Bauer, D. et al., 1993, Identification of Differentially Expressed mRNA Species by an Improved Display Technique (DDRT PCR) , Nucleic Acids Res. 21:4272 4280. * |
Bogler, O. et al., 1995, "The p53 Gene and Its Role in Human Brain Tumors", Glia 15:308-327. |
Bogler, O. et al., 1995, The p53 Gene and Its Role in Human Brain Tumors , Glia 15:308 327. * |
Chen, J. et al., 1995, "Effects of the MYC Oncogene Antagonists, MAD, on Proliferation, Cell Cycling and the Malignant Phenotype of Human Brain Tumour Cells", Nature Med. 1;638-643. |
Chen, J. et al., 1995, Effects of the MYC Oncogene Antagonists, MAD, on Proliferation, Cell Cycling and the Malignant Phenotype of Human Brain Tumour Cells , Nature Med. 1;638 643. * |
Eibl, R. et al., 1995, "Expression of Variant CD44 Epitopes in Human Astrocytic Brain Tumors", J. of Neurooncol. 26:165-170. |
Eibl, R. et al., 1995, Expression of Variant CD44 Epitopes in Human Astrocytic Brain Tumors , J. of Neurooncol. 26:165 170. * |
Elliot, P.J. et al., 1996, "Intravenous RMP-7 Selectively Increases Uptake of Carboplatin into Rat Brain Tumors", Cancer Res. 56:3998-4005. |
Elliot, P.J. et al., 1996, Intravenous RMP 7 Selectively Increases Uptake of Carboplatin into Rat Brain Tumors , Cancer Res. 56:3998 4005. * |
Faillot, T. et al., 1996, "A Phase I Study of an Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant Gliomas", Neurosurgery 39:478-483. |
Faillot, T. et al., 1996, A Phase I Study of an Anti Epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of Malignant Gliomas , Neurosurgery 39:478 483. * |
Fanger and Drakeman, 1995, "By Combining the Well-Known Specificity of Monoclonal Antibodies with New Insights into How the Immune System is Triggered, Bispecifics May Become Highly Promising Therapeutic Products Offering a Very Efficient and Well-Tolerated Approach to the Immunotherapy of Life-Threatening Diseases", DN&P 3:133-137. |
Fanger and Drakeman, 1995, By Combining the Well Known Specificity of Monoclonal Antibodies with New Insights into How the Immune System is Triggered, Bispecifics May Become Highly Promising Therapeutic Products Offering a Very Efficient and Well Tolerated Approach to the Immunotherapy of Life Threatening Diseases , DN&P 3:133 137. * |
Furnari, F. et al., 1995, "Genetics and Malignant Progression of Human Brain Tumours", Cancer Surv. 25:233-275. |
Furnari, F. et al., 1995, Genetics and Malignant Progression of Human Brain Tumours , Cancer Surv. 25:233 275. * |
Hadman, M. et al. 1995, "Modifications to the Differential Display Technique Reduce Background and Increase Sensitivity", Anal. Biochem. 226:383-386. |
Hadman, M. et al. 1995, Modifications to the Differential Display Technique Reduce Background and Increase Sensitivity , Anal. Biochem. 226:383 386. * |
Ikonomov, O. et al., 1996, "Differential Display Protocol with Selected Primers that Preferentially Isolates mRNAs of Moderate- to Low-Abundance in a Microscopic System", Biotechniques 20:1030-1042. |
Ikonomov, O. et al., 1996, Differential Display Protocol with Selected Primers that Preferentially Isolates mRNAs of Moderate to Low Abundance in a Microscopic System , Biotechniques 20:1030 1042. * |
Jung, J. et al., 1995, "Increased Levels of p21WAF1/Cip1 in Human Brain Tumors", Oncogene 11:2021-2028. |
Jung, J. et al., 1995, Increased Levels of p21 WAF1/Cip1 in Human Brain Tumors , Oncogene 11:2021 2028. * |
Laws and Thapar, 1993, "Brian Tumors", CA Cancer J. Clin. 43:263-271. |
Laws and Thapar, 1993, Brian Tumors , CA Cancer J. Clin. 43:263 271. * |
Liang and Pardee, 1992, "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction", Science 257:967-971. |
Liang and Pardee, 1992, Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction , Science 257:967 971. * |
Liang, P. et al., 1992, "Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelial Cells", Cancer Res. 52:6966-6968. |
Liang, P. et al., 1992, Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelial Cells , Cancer Res. 52:6966 6968. * |
Parker, S. et al., 1996, "Cancer Statistics", CA Cancer J. Clin. 46:5-28. |
Parker, S. et al., 1996, Cancer Statistics , CA Cancer J. Clin. 46:5 28. * |
Previtali, S. et al., 1996, "α6β4 and α6β1 Integrins in Astrocytomas and Other CNS Tumors", Neuropathol. Exp. Neurol. 55:456-465. |
Previtali, S. et al., 1996, 6 4 and 6 1 Integrins in Astrocytomas and Other CNS Tumors , Neuropathol. Exp. Neurol. 55:456 465. * |
Takano, S. et al., 1996, "Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients", Cancer Res. 56:2185-2190. |
Takano, S. et al., 1996, Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients , Cancer Res. 56:2185 2190. * |
Tsuzuki, T. et al., 1996, "Alterations of Retinoblastoma, p53, p16(CDKN2), and p15 Genes in Human Astrocytomas", Cancer 78:287-293. |
Tsuzuki, T. et al., 1996, Alterations of Retinoblastoma, p53, p16(CDKN2), and p15 Genes in Human Astrocytomas , Cancer 78:287 293. * |
Yamamoto, M. et al., 1996, "Differential Expression of Membrane-Type Matrix Metalloproteinase and Its Correlation with Gelatinase A Activation in Human Malignant Brain Tumors in Vivo and in Vitro" Cancer Res. 56:384-392. |
Yamamoto, M. et al., 1996, Differential Expression of Membrane Type Matrix Metalloproteinase and Its Correlation with Gelatinase A Activation in Human Malignant Brain Tumors in Vivo and in Vitro Cancer Res. 56:384 392. * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1829888A1 (en) | 2000-05-02 | 2007-09-05 | Yale University | Anti-inflammatory compounds and uses thereof |
EP2314601A1 (en) | 2000-05-02 | 2011-04-27 | Yale University | Anti-inflammatory compounds and uses thereof |
US20020164624A1 (en) * | 2001-02-12 | 2002-11-07 | Waldemar Debinski | VEGF-D expression in brain cancer |
WO2004050007A2 (en) * | 2002-11-29 | 2004-06-17 | Develogen Ag | Mammalian bt-42 proteins involved in the regulation of energy homeostasis |
WO2004050007A3 (en) * | 2002-11-29 | 2005-07-07 | Develogen Ag | Mammalian bt-42 proteins involved in the regulation of energy homeostasis |
US20130158113A1 (en) * | 2011-06-10 | 2013-06-20 | Golden Biotechnology Corporation | Methods and compositions for treating brain cancer |
Also Published As
Publication number | Publication date |
---|---|
WO1998019692A1 (en) | 1998-05-14 |
AU5199698A (en) | 1998-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU766675B2 (en) | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis | |
US20060269558A1 (en) | Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors | |
US5928884A (en) | FHIT proteins and nucleic acids and methods based thereon | |
US6242212B1 (en) | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins | |
US6359193B1 (en) | Nucleotide sequences of lats genes | |
US6863887B1 (en) | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis | |
US7160868B2 (en) | Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors | |
US5874290A (en) | Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon | |
AU728798B2 (en) | Vertebrate deltex proteins, nucleic acids, and antibodies, and related methods and compositions | |
US5990294A (en) | Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NORTHWEST BIOTHERAPEUTICS LLC, WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MURPHY, GERALD P.;BOYNTON, ALTON L.;SEHGAL, ANIL;REEL/FRAME:008371/0856 Effective date: 19970116 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: TOUCAN CAPITAL FUND II, L.P., MARYLAND Free format text: SECURITY AGREEMENT;ASSIGNOR:NORTHWEST BIOTHERAPEUTICS, INC.;REEL/FRAME:014567/0206 Effective date: 20040426 |
|
AS | Assignment |
Owner name: TOUCAN CAPITAL FUND II, L.P., MARYLAND Free format text: SECURITY AGREEMENT;ASSIGNOR:NORTHWEST BIOTHERAPEUTICS, INC.;REEL/FRAME:015093/0483 Effective date: 20040730 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |
|
AS | Assignment |
Owner name: NORTHWEST BIOTHERAPEUTICS, INC., WASHINGTON Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:TOUCAN CAPITAL FUND II, L.P.;REEL/FRAME:027956/0406 Effective date: 20120329 |
|
AS | Assignment |
Owner name: FOUR M PURCHASERS, LLC, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:NORTHWEST BIOTHERAPEUTICS, INC.;REEL/FRAME:028069/0752 Effective date: 20120402 |